<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002832.pub2" GROUP_ID="SCHIZ" ID="992000060912201149" MERGED_FROM="" MODIFIED="2014-01-14 13:14:30 +0000" MODIFIED_BY="Claire Irving" REVIEW_NO="1087" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2014-01-14 13:14:30 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Perazine for schizophrenia</TITLE>
<CONTACT MODIFIED="2014-01-14 13:14:30 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-01-14 13:14:30 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON><PERSON ID="z1301311112022346974199538643931" ROLE="AUTHOR"><FIRST_NAME>Bartosz</FIRST_NAME><LAST_NAME>Helfer</LAST_NAME><POSITION>Research Assistant</POSITION><EMAIL_1>bartosz.helfer@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><REGION>Bavaria</REGION><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON><PERSON ID="1184FD3182E26AA201DC7B3ED3CB490C" ROLE="AUTHOR"><FIRST_NAME>Benno</FIRST_NAME><LAST_NAME>Hartung</LAST_NAME><POSITION>Resident</POSITION><EMAIL_1>benno.hartung@gmx.de</EMAIL_1><EMAIL_2>Benno.Hartung@med.uni-duesseldorf.de</EMAIL_2><ADDRESS><DEPARTMENT>Institute for Legal Medicine</DEPARTMENT><ORGANISATION>University Hospital Duesseldorf</ORGANISATION><ADDRESS_1>Moorenstr. 5</ADDRESS_1><CITY>Duesseldorf</CITY><ZIP>40225</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 211 81 19362</PHONE_1><FAX_1>+49 211 81 19366</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-12-11 09:24:46 +0000" MODIFIED_BY="John  Rathbone">
<UP_TO_DATE>
<DATE DAY="17" MONTH="2" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="7" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="22" MONTH="6" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2013-12-11 09:37:48 +0000" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-12-11 09:24:28 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>Review updated with new trials but no overall changes to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-12-11 09:37:48 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>Results of update search in July 2012 added to review; risk of bias tables and description of bias added; background information, results and discussion extended; structure of the review updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-07-10 13:01:52 +0100" MODIFIED_BY="Claire Irving">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-07-10 13:01:52 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-15 15:17:00 +0000" MODIFIED_BY="Claire Irving">
<DATE DAY="11" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 10:42:17 +0000" MODIFIED_BY="Claire Irving">
<DATE DAY="31" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-12-11 10:02:17 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-12-11 10:02:17 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-31 14:01:21 +0000" MODIFIED_BY="[Empty name]">Perazine for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2013-12-11 10:02:17 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is often a severe and disabling illness that affects approximately one per cent of the worldwide population. Schizophrenia has 'positive' symptoms, such as strange and fixed beliefs (delusions), as well as hearing voices and seeing things (hallucinations). Schizophrenia also has 'negative' symptoms such as apathy, loss of emotion, lack of drive and disorganisation of behaviour and thought. The degree of disability is considerable with 80% - 90% not working and up to 10% dying.</P>
<P>Antipsychotic drugs are the main treatment for schizophrenia, and are grouped into older drugs (first generation or &#8216;typical&#8217;) and newer drugs (second generation or &#8216;atypical&#8217;). However, antipsychotic drugs also have serious side effects, particularly movement disorders such as uncontrollable shaking, tremors, muscle stiffness, tiredness, weight gain and the inability to sit still.</P>
<P>Perazine is an older antipsychotic drug first introduced in the 1950s. It is suggested to have a low level of side effects (especially for movement disorders). Its use is regional and restricted to countries like Germany, Poland, the Netherlands and the former Yugoslavia.</P>
<P>A search for trials was carried out in July 2012. The review now includes seven studies with a total of 479 participants and assesses the effects of perazine for people with schizophrenia. Comparisons of perazine versus placebo (&#8216;dummy&#8217; treatment) and versus other antipsychotic drugs revealed no clear differences or superiority of perazine. However, only a handful of studies have been undertaken and the number of participants in each study was small. In addition the studies avialable were of limited quality with data for the main outcomes of interest rated as low or very low quality. As perazine is a cheap drug and there is some limited evidence that it may cause less side effects than other older antipsychotic drugs, further large scale, well designed and well-reported studies are much needed.</P>
<P>This plain language summary has been written by a consumer Benjamin Gray from Rethink Mental Illness,</P>
<P>Email: <A HREF="mailto:ben.gray@rethink.org">ben.gray@rethink.org</A>.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-12-11 09:49:08 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Perazine is an old phenothiazine derivative used for the treatment of people with schizophrenia and is reputed to have a low level of extrapyramidal adverse effects. As far as we are aware, its use is limited to Germany, Poland, the former Yugoslavia and the Netherlands.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-12-11 09:37:48 +0000" MODIFIED_BY="[Empty name]">
<P>To examine the effects of perazine for those with schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medications.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-12-11 09:37:48 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group Trials Register, which includes relevant randomised controlled trials from the bibliographic databases Biological Abstracts, CINAHL, <I>The Cochrane Library</I>, EMBASE, MEDLINE, PsycLIT, LILACS, PSYNDEX, Sociological Abstracts and Sociofile. We searched the references of all included studies for further trials. We contacted pharmaceutical companies and authors of trials. We updated this search on 16th July 2012.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-12-11 09:37:48 +0000" MODIFIED_BY="[Empty name]">
<P>We selected all randomised controlled trials that compared perazine with other treatments for people with schizophrenia or schizophrenia-like psychoses, or both.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-12-11 09:37:48 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors (SL, BH, BHe) independently inspected the citations and where possible abstracts and ordered papers for re-inspection and quality assessment. We independently extracted data. We calculated the risk ratio (RR) and 95% confidence interval (CI) using a random-effects model. For continuous data, we calculated mean differences (MD). We inspected all data for heterogeneity, assessed trials for risk of bias and created summary of findings tables using GRADE.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-12-11 09:49:08 +0000" MODIFIED_BY="[Empty name]">
<P>The review now includes seven trials with a total of 479 participants. In only one trial, with 95 participants, perazine appeared superior to 'active placebo' (trimipramine) at five weeks for the outcome of 'no important global improvement' (n = 95, RR 0.43 CI 0.2 to 0.8, <I>low quality evidence</I>), but there was no statistically significant difference in most measures of mental state. Perazine did not induce more general adverse events than placebo but more participants received at least one dose of antiparkinson medication (n = 95, RR 4.50 CI 1.0 to 19.5, <I>very low quality evidence</I>).</P>
<P>Six small trials comparing perazine with other antipsychotics, including 384 participants in total, were incompletely reported and the outcomes were presented in various ways so that meta-analysis was not possible on most occasions. In the six studies, a similar number of participants receiving perazine or comparator antipsychotics (amisulpride, haloperidol, olanzapine, ziprasidone, zotepine) left the studies early (n = 384, RR 0.97 CI 0.68 to 1.38, <I>low quality evidence</I>). The results on efficacy could not be meta-analysed because the authors presented their results in very different ways. No obvious differences in adverse events between perazine and other antipsychotics could be derived from the limited data. Two haloperidol comparisons did not present extrapyramidal side-effects in a way that was suitable for use in meta-analysis, but three small comparisons with the second-generation antipsychotics zotepine and amisulpride showed no higher risk of akathisia (n = 111, RR 0.31 CI 0.1 to 1.1), dyskinesia (n = 111, RR 0.47 CI 0.1 to 3.5), parkinsonism (n = 81, RR 1.21 CI 0.5 2.8) or tremor (n = 40, RR 0.80 CI 0.3 to 2.6) with perazine.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-12-11 09:37:48 +0000" MODIFIED_BY="[Empty name]">
<P>The number, size and reporting of randomised controlled perazine trials are insufficient to present firm conclusions about the properties of this antipsychotic. It is possible that perazine is associated with a similar risk of extrapyramidal side-effects as some atypical antipsychotics but this is based on small comparisons. This should be clarified in larger, well-designed trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-12-11 09:37:48 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is often a chronic and disabling psychiatric disorder. It afflicts approximately 1% of the population worldwide with few gender differences. Its typical manifestations are 'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations); 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought; and catatonic symptoms such as mannerisms and bizarre posturing (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The degree of suffering and disability is considerable with 80% to 90% of those affected not working (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and up to 10% dying (<LINK REF="REF-Tsuang-1978" TYPE="REFERENCE">Tsuang 1978</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-12-11 09:37:48 +0000" MODIFIED_BY="[Empty name]">
<P>Perazine is a phenothiazine derivative which has been used as an antipsychotic in Germany since 1958. It is usually taken by mouth but an intramuscular formulation for the rapid treatment of very acutely disturbed psychotic patients is also available. It was developed and tested soon after chlorpromazine in the 1950s.</P>
<P>The customary dose range recommended for this antipsychotic under inpatient conditions is 75 to 600 mg/day (maximum 1000 mg/day). In acutely ill and severely disturbed patients, 50 mg perazine at time intervals of 30 minutes can be administered intramuscularly (<LINK REF="REF-Benkert-1996" TYPE="REFERENCE">Benkert 1996</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-12-11 09:37:48 +0000" MODIFIED_BY="[Empty name]">
<P>Perazine has a dopamine receptor binding action, which is similar to that of chlorpromazine and lower than that of haloperidol (<LINK REF="REF-Seeman-1981" TYPE="REFERENCE">Seeman 1981</LINK>). This suggests that the risk of extrapyramidal adverse effects should be lower than high potency antipsychotics such as haloperidol. This low risk of extrapyramidal adverse effects might also be enhanced by a rather high binding affinity for cholinergic receptors that counteract dopamine receptor blockade (<LINK REF="REF-Menge-1988" TYPE="REFERENCE">Menge 1988</LINK>). Perazine is also a potent inhibitor of central histaminergic receptors, which explains its sedating effects. These can be of benefit in the case of psychotic agitation (<LINK REF="REF-Menge-1988" TYPE="REFERENCE">Menge 1988</LINK>). Antagonistic effects on alpha-1 adrenergic receptors can be associated with cardiovascular adverse effects. Perazine has two metabolites, desmethyl-perazin and perphenazine-sulfoxide, which do not seem to have clinically significant effects (<LINK REF="REF-Menge-1988" TYPE="REFERENCE">Menge 1988</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Early uncontrolled studies of perazine suggested good efficacy for the treatment of acutely ill people with schizophrenia (<LINK REF="REF-Enss-1958" TYPE="REFERENCE">Enss 1958</LINK>). Other open studies evaluated the use of perazine for antipsychotic relapse prevention and yielded promising results, especially as the rate of extrapyramidal adverse effects appeared to be low (<LINK REF="REF-Hippius-1962" TYPE="REFERENCE">Hippius 1962</LINK>; <LINK REF="REF-Kr_x00fc_ger-1963" TYPE="REFERENCE">Krüger 1963</LINK>; <LINK REF="REF-Grohmann-1988" TYPE="REFERENCE">Grohmann 1988</LINK>). However, although perazine is frequently used in Germany, we understand its current use is limited to only a few other countries, Poland, the Netherlands and former Yugoslavia. We felt it important to evaluate the evidence derived from randomised controlled trials of an antipsychotic with regionally restricted use.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>To examine the effects of perazine for those with schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medications.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>We included all relevant randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>We included people with the diagnosis of schizophrenia, however diagnosed. We also included those with 'serious or chronic mental illness' or 'psychotic illness'. If possible, we excluded people with schizoaffective disorder, dementing illnesses, depression and problems primarily associated with substance misuse.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. Perazine monotherapy, any dose and pattern of administration. If different doses of perazine were randomised, we included these studies if there was also a comparison with a second drug, placebo or no treatment.<BR/>2. Placebo or no treatment.<BR/>3. Monotherapy with other antipsychotic drugs, any dose or pattern of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>As schizophrenia is often a lifelong illness and perazine is used as an ongoing treatment, we grouped outcomes according to time periods: short term (up to three months), medium term (three months to one year) and long term (more than one year).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Clinical response</HEADING>
<P>1.1 Clinically significant response in global state - as defined by each of the studies (short term)</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Death - suicide or natural causes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Leaving the study early</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Service utilisation</HEADING>
<P>3.1 Hospital admission<BR/>3.2 Days in hospital<BR/>3.3 Change in hospital status</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Mental state</HEADING>
<P>4.1 Clinically significant response in mental state - as defined by each of the studies<BR/>4.2 Average score or change in mental state<BR/>4.3 Clinically significant response on positive symptoms - as defined by each of the studies<BR/>4.4 Average score or change in positive symptoms<BR/>4.5 Clinically significant response on negative symptoms - as defined by each of the studies<BR/>4.6 Average score or change in negative symptoms</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Behaviour</HEADING>
<P>5.1 Clinically significant response in behaviour (e.g. aggressive behaviour, behaviour on the ward etc.) - as defined by each of the studies<BR/>5.2 Average score or change in behaviour</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Extrapyramidal adverse effects</HEADING>
<P>6.1 Incidence of use of antiparkinson drugs<BR/>6.2 Clinically significant extrapyramidal adverse effects - as defined by each of the studies<BR/>6.3 Average score or change in extrapyramidal side-effects</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Other adverse effects, general and specific</HEADING>
<P>7.1 Number of people dropping out due to adverse affects<BR/>7.2 Cardiac effects<BR/>7.3 Anticholinergic effects<BR/>7.4 Antihistamine effects<BR/>7.5 Prolactin related symptoms</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Social functioning</HEADING>
<P>8.1 Clinically significant response in social functioning - as defined by each of the studies<BR/>8.2 Average score or change in social functioning</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. Economic outcomes</HEADING>
<P>10. Quality of life or satisfaction with care for either recipients of care or carers<BR/>10.1 Significant change in quality of life or satisfaction - as defined by each of the studies<BR/>10.2 Average score or change in quality of life or satisfaction<BR/>10.3 Employment status</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11. Cognitive functioning.</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">12. Summary of findings table</HEADING>
<P>We used the <A HREF="http://www.ims.cochrane.org/revman/gradepro">GRADE</A>approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and used the <A HREF="http://www.ims.cochrane.org/revman/gradepro">GRADE</A> profiler to import data from Review Manager (<A HREF="http://www.ims.cochrane.org/revman">RevMan</A>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes that we rated as important to patient care and decision making. We selected the following main outcomes for inclusion in the summary of findings table.</P>
<P>1. Global state.</P>
<P>2. Mental state (overall) - clinically significant response in mental state, as defined by each of the studies.</P>
<P>3. Acceptability of treatment (leaving the study early due to any reason).</P>
<P>4. Overall tolerability (leaving the study early due to adverse events).</P>
<P>5. Movement disorders (number of participants receiving antiparkinson medication at least once).</P>
<P>6. Satisfaction with care.</P>
<P>7. Quality of life.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Search methods for this 2012 update are below, for previous searches please see the <LINK TAG="APPENDICES" TYPE="SECTION">Appendices</LINK>.</P>
<P>No language restriction was applied within the limitations of the search tools.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Cochrane Schizophrenia Group Trials Register</HEADING>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group Trials Register (16th July 2012).</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Intervention search</HEADING>
<P>The &#8216;Intervention&#8217; field was searched using the phrase:</P>
<P>(*perazin* or *pernazin* or *taxilan* or *phenothiazine tran* or * piperazin*).</P>
<P>The Cochrane Schizophrenia Group Trials Register is compiled by systematic searches of major databases, handsearches of journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are screened by the Trial Search Co-ordinator and assigned to the awaiting classification section of relevant existing or new review titles.</P>
</SUBSECTION>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-02-07 16:44:26 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected the references of all identified studies for more citations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>We contacted the first author of each included study for more information regarding unpublished trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Drug company</HEADING>
<P>We contacted the manufacturers of proprietary perazine (Lundbeck, Kopenhagen) for additional data (first version only, not done for updates).</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Methods used in data collection and analysis for this 2012 update are below, for previous methods please see <LINK TAG="APPENDICES" TYPE="SECTION">Appendices</LINK>.</P>
<STUDY_SELECTION MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>For this 2012 update the review authors SL and BHe independently inspected citations from the new electronic search and identified relevant abstracts. SL and BHe also inspected full articles of the abstracts which might have met the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>Review authors SL and BH extracted the data from the included studies (first version, there were no new included studies in the 2012 update). We extracted data presented only in graphs and figures whenever possible. When further information was necessary, we contacted the authors of studies in order to obtain missing data or for clarification.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only if:<BR/>a. the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and<BR/>b. the measuring instrument has not been written or modified by one of the trialists for that particular trial.</P>
<P>Ideally the measuring instrument should either be: i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in the 'Description of studies'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided to primarily use endpoint data, and to only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences throughout the review (section 9.4.5.2 of <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion:</P>
<P>a) standard deviations and means are reported in the paper or obtainable from the authors;</P>
<P>b) when a scale starts from the finite number zero the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>));</P>
<P>c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2SD &gt; (S - S min), where S is the mean score and S min is the minimum score.</P>
<P>Endpoint scores on scales often have a finite start and endpoint, and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants in 'Other tables' within the 'Data and analyses' section rather than into a statistical analysis. Skewed data pose less of a problem when looking at the mean if the sample size is large; we entered such endpoint data into the syntheses.</P>
<P>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not, we entered skewed change data into analyses regardless of the size of the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>To facilitate comparisons between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (for example mean days per month).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS) (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>) this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>; <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Direction of graphs</HEADING>
<P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for perazine.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>For this 2012 update, BHe worked independently by using the criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess trial quality. SL supervised the process. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.</P>
<P>Where adequate details of randomisation and other characteristics of the trials were not provided, we contacted the authors of the studies in order to obtain additional information.</P>
<P>We have noted the level of risk of bias in both the text of the review and in the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). The number needed to treat or harm (NNT or H) statistic with its confidence interval is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta-analyses and its interpretation (<LINK REF="REF-Hutton-2009" TYPE="REFERENCE">Hutton 2009</LINK>). For binary data presented in the 'Summary of findings' tables, where possible, we calculated illustrative comparative risks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes we estimated the mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). If scales of very considerable similarity were used, we presumed there was a small difference in measurement and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster randomised trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data pose problems. Authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation coefficients for their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we presented these data as if from a non-cluster randomised study but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation coefficient (ICC) [Design effect = 1 + (m - 1) * ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies have been appropriately analysed, taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (for example pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason, cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we only used the data of the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary we simply added these and combined them within the two-by-two table. If data were continuous we combined the data following the formula in section 7.7.3.8 (Combining groups) of the <I>Cochrane Handbook for Systemic reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Where the additional treatment arms were not relevant, we did not reproduce these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Overall loss of credibility</HEADING>
<P>We agree that at some degree of loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). It is, however, unclear from which degree of loss to follow-up this becomes a problem. We therefore did not exclude studies on the basis of loss to follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Binary</HEADING>
<P>We presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those leaving the study early were assumed to have remained unchanged. This assumption is conservative for measures of response because those leaving the study early are assumed to have not responded. It is not conservative for side-effects. We however felt that it would often be an overestimation of the risk if all participants who left the studies early were assumed to have developed a side-effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Continuous</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Attrition</HEADING>
<P>We aimed to extract intention-to-treat data, but if these were not available we presented and used the data from the people who completed the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Standard deviations</HEADING>
<P>If standard deviations were not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but exact standard errors and confidence intervals available for group means, and either P values or T values available for differences in mean, we can calculate them according to the rules described in the <I>Cochrane Handbook for Systemic reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When only the standard error (SE) is reported, standard deviations (SDs) are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <I>Cochrane Handbook for Systemic reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) present detailed formulae for estimating SDs from P values, T or F values, confidence intervals, ranges or other statistics. If these formulae did not apply, we would calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Last observation carried forward</HEADING>
<P>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<LINK REF="REF-Leucht-2007" TYPE="REFERENCE">Leucht 2007</LINK>). We reproduced these data but readers should be aware of the problem.</P>
</SUBSECTION>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We initially considered all included studies, without seeing the comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we fully discussed them.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We initially considered all included studies, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we fully discussed them.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>We investigated heterogeneity between studies by considering the I<SUP>2 </SUP>statistic alongside the Chi<SUP>2</SUP> test P value. The I<SUP>2 </SUP>provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2 </SUP>depends on: i. the magnitude and direction of the effects and ii. strength of evidence for heterogeneity (for example P value from Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>). An I<SUP>2 </SUP>estimate greater than or equal to around 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic was interpreted as evidence of substantial levels of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in section 10 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects model method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. To us this often seems to be true, and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model as it puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect these studies can either inflate or deflate the effect size. We chose the random-effects model for all analyses. The reader is, however, able to choose to inspect the data using the fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Subgroup analyses</HEADING>
<P>We proposed to undertake this review and provide an overview of the effects of perazine for people with schizophrenia in general. Information about subgroups (including first episode of the illness, elderly patients, and patients with subtypes of schizophrenia) was missing in the available set of data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Investigation of heterogeneity</HEADING>
<P>If inconsistency was high, this was reported. First we investigated whether the data had been entered correctly. Second, if the data were correct, we looked to see if there were methodological reasons in the studies that accounted for the heterogeneity. Finally, the graph was visually inspected and studies outside of the company of the rest were successively removed to see if heterogeneity was restored. When unanticipated clinical or methodological heterogeneity was obvious we simply stated hypotheses regarding the heterogeneity for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these.</P>
<P/>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>We applied all sensitivity analyses to the primary outcomes of this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes we included these studies and if there was no substantive difference when the implied randomised studies were added to those with a better description of randomisation, then we entered all data from these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Imputed values</HEADING>
<P>We also undertook a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster randomised trials.</P>
<P>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool the data from the excluded trials with the other trials contributing to the outcome but presented them separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Fixed-effect and random-effects models</HEADING>
<P>All data were synthesised using a random-effects model, however we also synthesised the data for the primary outcome using a fixed-effect model to evaluate whether the greater weights assigned to larger trials with greater event rates altered the significance of the results compared to the more evenly distributed weights in the random-effects model.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>For a substantive description of studies please see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Please compare with <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Original search in 2000</HEADING>
<P>The original search of the Cochrane Schizophrenia Group (CSG) controlled Trials Register in the year 2000 yielded 40 studies ,which we ordered and inspected. After handsearching included trials and contacting the manufacturers of perazine, we did not identify any further trials. Sixteen publications of six studies met our inclusion criteria. Our contact with the first authors of the studies yielded no further studies or individual patient data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1. Update search in 2005</HEADING>
<P>The update search in the CSG controlled Trials Register in 2005 yielded 59 references. The vast majority of the references were clearly not related to perazine and hence we did not record them in the excluded studies table. We identified three references in two studies (<LINK REF="STD-Kemperdick-1967" TYPE="STUDY">Kemperdick 1967</LINK>; <LINK REF="STD-Loza-2001" TYPE="STUDY">Loza 2001</LINK>) that were classified as excluded studies. We identified three further references in studies that had already been included in the first version. Most noteworthy was the final journal publication of <LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK>. In contrast to the previously available abstracts and short versions of the trial, further outcome data were presented and some of the previously listed results had to be slightly changed because they were more clearly reported within the new reference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1. Update search in 2012</HEADING>
<P>The update search in 2012, made using the CSG controlled Trials Register, yielded four new references. Three studies did not meet the inclusion criteria. One was an additional publication of a study that had already been included (<LINK REF="STD-Dieterle-1991" TYPE="STUDY">Dieterle 1991</LINK>), one was not randomised and it was unclear whether the substance tested was perazine (<LINK REF="STD-Gerson-1964" TYPE="STUDY">Gerson 1964</LINK>), and one used an inappropriate comparison (<LINK REF="STD-Ohlmeier-2007" TYPE="STUDY">Ohlmeier 2007</LINK>). The fourth study was a randomised, open trial comparing perazine with olanzapine and ziprasidone that met the inclusion criteria (<LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>).</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>We included seven studies. Six trial centres were in Germany, one was in Poland.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Methods</HEADING>
<P>All included studies were described as randomised. Follow-up periods ranged from 28 to 84 days. All seven were short term (up to three months).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Participants</HEADING>
<P>All but one study (<LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>) of the included studies had less than 100 participants; the range was 23 to 191. A total of 479 people participated in the seven trials, most of whom had a diagnosis of schizophrenia. <LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK> also included participants with schizophreniform disorder, and <LINK REF="STD-R_x00fc_ther-1988" TYPE="STUDY">Rüther 1988</LINK> also included participants with schizophrenia-like disorders (for example schizoaffective disorder). We included these studies because the majority of randomised participants had schizophrenia.</P>
<P>Five studies used International Classification of Diseases-9 (ICD-9) criteria, <LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK> used Diagnostic and Statistical Manual of Mental Disorders-III-R (DSM-III-R), and <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK> used ICD-10. <LINK REF="STD-Klimke-1993" TYPE="STUDY">Klimke 1993</LINK>, <LINK REF="STD-R_x00fc_ther-1988" TYPE="STUDY">Rüther 1988</LINK> and <LINK REF="STD-Schmidt-1982" TYPE="STUDY">Schmidt 1982</LINK> included only "acutely ill" participants, <LINK REF="STD-Wetzel-1991" TYPE="STUDY">Wetzel 1991</LINK> restricted inclusion to participants with positive symptoms and <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK> to paranoid schizophrenia. <LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK> required a minimum score on the Brief Psychiatric Rating Scale (BPRS).</P>
<P>From those studies that included information on the gender of participants there were 169 males and 174 females. Ages ranged from 18 to 70 years; where the mean age was indicated it ranged between 31 and 37 years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Setting</HEADING>
<P>Five studies were from inpatient settings. In two studies (<LINK REF="STD-Dieterle-1991" TYPE="STUDY">Dieterle 1991</LINK>; <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>) the setting was not clear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Interventions</HEADING>
<P>The dose of perazine ranged between 75 and 1000 mg/day, with means between 300 and 650 mg/day where reported.</P>
<P>Only one study (<LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK>) was considered to be placebo-controlled. The comparator group received a tricyclic antidepressant, trimipramine. It turned out to be statistically significantly less effective than perazine at least according to the global impression of the raters. It was regarded as an active placebo.</P>
<P>Two studies compared perazine with oral haloperidol. Four studies compared perazine with the second-generation antipsychotics zotepine (<LINK REF="STD-Dieterle-1991" TYPE="STUDY">Dieterle 1991</LINK>; <LINK REF="STD-Wetzel-1991" TYPE="STUDY">Wetzel 1991</LINK>), amisulpride (<LINK REF="STD-R_x00fc_ther-1988" TYPE="STUDY">Rüther 1988</LINK>), and ziprasidone and olanzapine in <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>, which was a three-arm study. In these trials perazine was used as the gold standard for the evaluation of the second-generation antipsychotics.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Outcomes</HEADING>
<P>Many outcomes were presented as scale-derived, continuous data. Often we could not use the data for meta-analytic calculations because they were either skewed or the standard deviations were not indicated. Despite letters sent to the study authors (not done for the 2012 update), no original patient data that could have been dichotomised were obtained.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Scales</HEADING>
<P>Details of the scales that provided usable data are shown below.</P>
<SUBSECTION>
<HEADING LEVEL="4">6.1. Global state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1.1 Clinical Global Impression (CGI)</HEADING>
<P>CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) is a rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually employed with low scores indicating decreased severity or greater recovery. Usable data were reported by <LINK REF="STD-R_x00fc_ther-1988" TYPE="STUDY">Rüther 1988</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.1.2 Global Assessment Scale (GAS)</HEADING>
<P>In the GAS (<LINK REF="REF-Endicott-1976" TYPE="REFERENCE">Endicott 1976</LINK>) a clinician rates the overall functioning of a patient on a scale of 1 to 100. Lower scores indicate poorer functioning. Usable data were reported by <LINK REF="STD-Wetzel-1991" TYPE="STUDY">Wetzel 1991</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.2. Mental state</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.2.1 Brief Psychiatric Rating Scale (BPRS)</HEADING>
<P>BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) is a brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0 to 6 or 1 to 7. Scores can range from 0 to 126, with high scores indicating more severe symptoms. Usable data were reported by <LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK>, <LINK REF="STD-Dieterle-1991" TYPE="STUDY">Dieterle 1991</LINK>, <LINK REF="STD-Schmidt-1982" TYPE="STUDY">Schmidt 1982</LINK> and <LINK REF="STD-Wetzel-1991" TYPE="STUDY">Wetzel 1991</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2.2 Positive and Negative Syndrome Scale (PANSS)</HEADING>
<P>PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>) is a schizophrenia scale that has 30 items, each of which can be defined on a seven-point scoring system varying from 1 - absent to 7 - extreme. It can be divided into three subscales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity. Useable data (percentage PANSS total score from baseline) were obtained for <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.3. Missing outcomes</HEADING>
<P>Relapse, issues of hospital admission, behaviour, cognitive functions, cost issues, quality of life and satisfaction with care were not addressed in the included studies.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>The majority of excluded studies were not stated to be randomised (n = 19). One study was excluded because it did not examine participants with schizophrenia, one used wrong interventions, and three did not provide any useable outcomes.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>For graphical representations of our judgements of risk of bias please refer to <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. Full details of judgements can be seen in the 'Risk of bias' tables.<BR/>
</P>
<ALLOCATION MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>In only two studies (<LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK>: randomisation schedule generated by a validated computer program, <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>: randomisation programme written by statistician) was the method used to generate random allocation described. These two studies were classified as having a low risk of selection bias. None of the other studies provided a specific method used in the randomisation procedure and thus they were classified as having an unclear risk of selection bias.</P>
<P>Although no differences in baseline descriptions of the comparator groups were found on most occasions, the readers were given little assurance that bias was minimised during the allocation procedure in these other trials.</P>
<P>As for the allocation concealment, all studies were classified as unclear in this respect except for <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK> (see risk of bias table).</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Precautions taken to ensure blinding were described in three studies. Two used identical capsules (<LINK REF="STD-Dieterle-1991" TYPE="STUDY">Dieterle 1991</LINK>; <LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK>), whereas in the third study blinding was attempted by treating one group with perazine tablets and placebo liquid and the other group with haloperidol liquid and placebo pills (<LINK REF="STD-Schmidt-1982" TYPE="STUDY">Schmidt 1982</LINK>). <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK> was an open trial; and the remaining trials reported that they were blind but did not describe the methods of blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>In all seven studies data were presented on losses to follow-up.</P>
<P>Although all studies indicated the numbers of participants who left the study before its completion, the reasons for leaving the studies early were not consistently indicated.</P>
<P>Two studies were assessed as having a low risk of attrition bias, meaning that the problem of incomplete outcome data was addressed in an appropriate way (the number of dropouts was not very high and was evenly distributed between groups). Another two studies were judged as unclear, and another and the last three as having high risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Four out of seven studies were judged as having a high risk of reporting bias due to the lack of information about some predefined outcomes. Standard deviations and means were often missing. The remaining three studies did not selectively report on any outcomes and thus were judged as having a low risk of bias in that respect.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-02-17 15:16:35 +0000" MODIFIED_BY="[Empty name]">
<P>The included studies were free of any other clear sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Comparison 1: Perazine versus placebo</HEADING>
<P>Ninety-five participants from one study (<LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK>) were randomised to this comparison.</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Leaving the study early</HEADING>
<P>No significant difference between perazine and trimipramine was found for the outcome 'leaving the study early for any reason' (n = 95, RR 0.62 CI 0.4to 1.1) and 'due to inefficacy of treatment' (n = 95, RR 0.30 CI 0.09 to 1.04, p = 0.06). The number of participants 'leaving the study early for adverse events' was not indicated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Global state</HEADING>
<P>For change in global state over time, one small five-week study (<LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK>) demonstrated a statistically significant difference between perazine and the tricyclic antidepressant trimipramine, which was considered to be an active placebo (n = 95, RR 0.43 CI 0.2 to 0.8). The definition of the response criterion was unimproved or worse according to the clinical global impression of the raters.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Mental state</HEADING>
<P>Using a cut-off of less than 20% BPRS reduction (n = 95, RR 0.70 CI 0.5 to 1.1) or less than 30% BPRS reduction (n = 95, RR 0.82 CI 0.6 to 1.1) no statistically signficant difference in the number of responders was found. The mean BPRS at the endpoint was not significantly different between both groups (n = 79, MD -6.20 CI -13.2 to 0.8). Results on the mean change of BPRS from baseline to the endpoint differed depending on whether the results were analysed in an intention-to-treat or a per protocol analysis. In the former a significant superiority of perazine compared to active placebo was found (n = 95, MD -7.10 CI -13.5 to -0.7), while the latter showed no significant difference (n = 79, MD -6.10 CI -13.1 to 0.9). Therefore, this result must be interpreted with caution. Further data from two studies on the BPRS at the endpoint (<LINK REF="STD-R_x00fc_ther-1988" TYPE="STUDY">Rüther 1988</LINK>) and the Association for Methodology and Documentation in Psychiatry (AMDP) system (<LINK REF="STD-Schmidt-1982" TYPE="STUDY">Schmidt 1982</LINK>) could only be presented in 'Other data' tables because they were skewed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Adverse events</HEADING>
<P>We found no significant differences in terms of 'at least one adverse event' (n = 95, RR 1.15 CI 0.9 to 1.5) and 'at least one extrapyramidal side-effect' (n = 95, RR 13.53 CI 0.8 to 230.4). However, significantly more people in the perazine group received at least one dose of antiparkinson medication (n = 95, RR 4.50 CI 1.04 to 19.5).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Other outcomes</HEADING>
<P>No data were presented on the other outcomes listed in our methods section.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Comparison 2: Perazine versus other antipsychotics</HEADING>
<P>A total of 384 patients from six studies were randomised to this comparison. Two studies used haloperidol as a comparator (<LINK REF="STD-Schmidt-1982" TYPE="STUDY">Schmidt 1982</LINK>; <LINK REF="STD-Klimke-1993" TYPE="STUDY">Klimke 1993</LINK>). The other three studies used atypical antipsychotics, one amisulpride (<LINK REF="STD-R_x00fc_ther-1988" TYPE="STUDY">Rüther 1988</LINK>), one olanzapine and ziprasidone (<LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>), and two zotepine (<LINK REF="STD-Dieterle-1991" TYPE="STUDY">Dieterle 1991</LINK>; <LINK REF="STD-Wetzel-1991" TYPE="STUDY">Wetzel 1991</LINK>), with perazine being used as the gold standard for the evaluation of the atypical antipsychotics.</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Leaving the study early</HEADING>
<P>All six studies could be used for the outcome 'leaving the study early' and no difference was found between perazine and the other antipsychotics (n = 384, RR 0.97 CI 0.68 to 1.38).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Global state</HEADING>
<P>According to limited data from one study (<LINK REF="STD-Wetzel-1991" TYPE="STUDY">Wetzel 1991</LINK>), participants allocated to perazine were as likely to be 'no better or worse' than those given amisulpride (n = 30, RR 1.33 CI 0.4 to 5.0) but had a higher mean severity of illness according to the Clinical Global Impression Scale (n = 30, MD 1.85 CI 1.01 to 2.7) and a higher severity of illness according to the Global Assessment Scale in the zotepine comparison (n = 41, MD -10.0 CI -17.1 to -2.9).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Mental state</HEADING>
<P>As with the global outcomes, mental state data were reported in a variety of ways hampering comparison.<BR/>
<LINK REF="STD-Schmidt-1982" TYPE="STUDY">Schmidt 1982</LINK> reported no significant difference between perazine and haloperidol on 'no better or worse' (BPRS, n = 32, RR 1.18 CI 0.5 to 2.6). Reporting endpoint BPRS data, <LINK REF="STD-Wetzel-1991" TYPE="STUDY">Wetzel 1991</LINK> showed zotepine as significantly superior to perazine (n = 34, MD 7.92 CI 1.1 to 14.7); however, using a different method to calculate this outcome, <LINK REF="STD-Dieterle-1991" TYPE="STUDY">Dieterle 1991</LINK> reported the superiority of perazine compared to zotepine (n = 40, MD -0.40 CI -0.7 to -0.1). If we understand <LINK REF="STD-Dieterle-1991" TYPE="STUDY">Dieterle 1991</LINK> correctly, they calculated the mean score of all BPRS items first for each patient and then calculated the mean of all patients. <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK> presented the percentage PANSS total score change from baseline and found no difference between perazine and olanzapine or ziprasidone.</P>
<P>
<LINK REF="STD-Dieterle-1991" TYPE="STUDY">Dieterle 1991</LINK> also presented data on the positive symptoms subscore of the BPRS and found significant superiority of perazine compared to zotepine (n = 40, MD -0.40, CI -0.8 to -0.02).</P>
<P>The BPRS data from <LINK REF="STD-R_x00fc_ther-1988" TYPE="STUDY">Rüther 1988</LINK> and the AMDP data from <LINK REF="STD-Schmidt-1982" TYPE="STUDY">Schmidt 1982</LINK> appeared to be skewed so we were unable to analyse them (numbers are presented in the 'Other data' table).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Adverse events</HEADING>
<P>The reporting of adverse events was incomplete in the included studies. Concerning extrapyramidal side-effects, no statistically significant differences in terms of akathisia (n = 111, RR 0.31 CI 0.1 to 1.1), dyskinesia (n = 111, RR 0.47 CI 0.1 to 3.5), parkinsonism (n = 81, RR 1.21 CI 0.5 to 2.8) or tremor (n = 80, RR 0.80 CI 0.3 to 2.6) were found between perazine and the atypical antipsychotics zotepine and amisulpride. With the exception of one case of neuroleptic malignant syndrome in the study by <LINK REF="STD-Schmidt-1982" TYPE="STUDY">Schmidt 1982</LINK> (equivocal data, n = 32, RR 0.30 CI 0.01 to 6.8) no data on extrapyramidal side-effects could be used from the three haloperidol comparisons due to poor reporting.</P>
<P>A similar number of participants in five studies left the studies earlier due to adverse events (n = 193, RR 0.87 CI 0.4 to 1.9).</P>
<P>The incidence of anticholinergic side-effects (two studies), arousal (one study), orthostatic hypotension (two studies), laboratory abnormalities (three studies), hypersalivation (one study), vegetative disorders (one study), electroencephalogram (EEG) changes (one study) and increase in transaminase (one study) were found to be similar for both groups. However, the equivalence of these two compounds cannot be assumed in this respect due to small numbers and insufficient power.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Other outcomes</HEADING>
<P>No data were presented on all other outcomes listed in our method section.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Publication bias, subgroup and sensitivity analyses</HEADING>
<P>Due to the paucity of studies we were unable to perform subgroup and sensitivity analyses or tests for publication bias as set out in the methods section. If more trials are published, these analyses will be completed in future updates of this review. The use of the fixed-effect model did not lead to substantially different results compared to the random-effects model in terms of the primary outcome.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Six out of the seven randomised trials were undertaken in Germany, and one in Poland, which limits the generalisability of the results to other countries. Furthermore, most of the studies were undertaken in hospital settings. Although the studies involved people with a clear diagnosis of schizophrenia, it is difficult to make a definite statement on generalisability because the reports do not describe how many patients who would have met the inclusion criteria were not enrolled in the trials. The trials were all classified as short term, so the long-term effects of perazine for an often chronic disorder were not assessed. Specific data for those presenting with a first episode of the illness, elderly patients, and patients with subtypes of schizophrenia are missing. The limitations in the available data are also reflected in the risk of bias table and the summary of findings table.</P>
<SUMMARY_OF_RESULTS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">1. Comparison 1: Perazine versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">1.1 General</HEADING>
<P>Surprisingly, the only trial which could be considered as a comparison of perazine with active placebo was the second most recently published one (<LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK>); therefore perazine has been used for several decades without evidence derived from randomised controlled trials that it is more effective than placebo. This illustrates the dramatic shift of research paradigms and the recent increase in requirements for new drugs to be prescribed to patients. It is of course debatable whether the comparator in the trial, trimipramine, can be considered to be an 'active placebo'. Trimipramine is a tricyclic antidepressant and antidepressants have not been shown to have important antipsychotic effects. But the hypothesis of the trial was that trimipramine may have such properties because it affects the dopamine system. Given the paucity of data on perazine in general, and since overall perazine was more effective than trimipramine in the study, we decided that for the purpose of this review this classification was acceptable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1.2 Leaving the study early</HEADING>
<P>A similar number of the participants treated with perazine and with trimipramine left the study early. This is surprising as it would be expected that a proper antipsychotic treatment would be more acceptable for those with schizophrenia than an antidepressant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1.3 Global state and mental state</HEADING>
<P>There are very little data, derived from one small trial with 95 participants, to suggest that more people with schizophrenia who are treated with perazine globally improve in the short term than those treated with an antidepressant. However, looking at the mental state result this finding was only confirmed in the intention-to-treat analysis of the BPRS change from baseline to endpoint and hence cannot be considered as robust.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1.4 Adverse events</HEADING>
<P>Compared to the original version, the update did provide some data on adverse events. While no differences in terms of the number of participants with 'any adverse event' and 'at least one extrapyramidal side-effect' were found, more participants in the perazine group received antiparkinson medication indicating movement disorders as an adverse event. This result could call into question our hypothesis in the first version of the review that perazine may be an 'atypical antipsychotic'. However, only 20% of people in the perazine group received antiparkinson medication. This is a similar rate to that of atypical antipsychotics such as olanzapine (16%) (<LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK>). The fact that perazine induced significantly more movement disorders than 'active placebo' in this trial may be due to the anticholinergic effects of trimipramine. The studies on atypical antipsychotics used real placebo so that withdrawal extrapyramidal symptoms may have occurred in the placebo groups and obscured any differences between the groups. We would therefore like to maintain the hypothesis that perazine could be an atypical antipsychotic, but given the small amount of available data this is at present mere speculation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">2. Comparison 2: Perazine versus other antipsychotics</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">2.1 General</HEADING>
<P>We were pleasantly surprised that in 2012 another perazine randomised controlled trial has been published, it is the largest included study (<LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>). We welcome the research interest in old compounds such as perazine, which can make valuable contributions to treatment. The overall results of this comparison cannot be regarded as conclusive due to the small numbers randomised to the studies and outcomes that were either poorly presented or presented in different ways that made meta-analysis impossible. On most occasions only one or two studies reported on an outcome in the same way.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2.2 Leaving the study early</HEADING>
<P>In these short-term studies 28% of those taking perazine and 30% in the control groups left before the trial was completed. This is a relatively low attrition rate compared to some trials dealing with newer antipsychotic drugs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2.3 Global state</HEADING>
<P>No usable data could be extracted from the trials comparing perazine with conventional antipsychotics such as haloperidol, thus it is not clear whether perazine is more or less effective in improving global state. According to two comparisons with the atypical antipsychotics zotepine and amisulpride, perazine faired worse regarding the mean global state of the participants at the end of the studies. Due to the very low number of participants that were randomised in these trials this result cannot be regarded as conclusive without further trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2.4 Mental state</HEADING>
<P>On analysing a small database containing the results of two trials, perazine had a similar efficacy compared to haloperidol for the improvement of mental state. The data from two studies comparing perazine with the newer antipsychotic zotepine are equivocal; one trial found zotepine to be superior, whereas <LINK REF="STD-Dieterle-1991" TYPE="STUDY">Dieterle 1991</LINK> favoured perazine in this regard. This might be the result of chance findings due to small sample sizes. The more reasonably sized study by <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK> (191 participants) found no difference between perazine and olanzapine or ziprasidone. Again, further larger trials are needed before definite conclusions can be drawn.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2.5 Adverse events</HEADING>
<P>Perazine was not associated with significantly more or fewer adverse events than the drugs in the control groups, but this result might not be a true reflection of effect because the single outcomes were mostly only reported by one or two trials. However, looking at the more global parameter 'leaving the studies earlier because of adverse events', for which five studies could be included, similar rates were found indicating that perazine might generally be as well tolerated as other currently used antipsychotics. Although in each of the haloperidol comparisons perazine was associated with fewer extrapyramidal side-effects, this could not be confirmed by a meta-analysis due to poor reporting of data. However, according to three studies comparing perazine with the newer antipsychotics amisulpride and zotepine, perazine had a similar extrapyramidal side-effect risk. It might therefore be possible that perazine has an atypical profile but, because of the low numbers of participants, more trials are necessary before we can reach a definite conclusion. Unfortunately the comparison of perazine with ziprasidone and olanzapine did not report side-effect data, thus nothing can be said about the relative effects (<LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>The number of included studies is too small to conclusively judge the potential applicability of the obtained results. Trials with small sample sizes lack sufficient power to detect a small to moderate effect, and thus results from such trials are often inconclusive even when a real effect does exist. A review suggested that meta-analyses based on the summation of small trials should be interpreted as inconclusive, regardless of whether the combined estimate was significant (<LINK REF="REF-Davey-Smith-1998" TYPE="REFERENCE">Davey Smith 1998</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>There were major limitations in study quality according to the risk of bias tool. In addition to this tool, only a secondary publication of one study reported that the assessors rating the outcome were independent of the treatment (<LINK REF="STD-Schmidt-1982" TYPE="STUDY">Schmidt 1982</LINK>). As the scale-rated outcomes were largely rated by a person who was unlikely to be disinterested in the final result, all results in this review need to be considered prone to bias. Continuous scale data were often poorly reported. Frequently they lacked explicit statements regarding the denominator or standard deviation, or were only presented in significance tests or within graphs. Three studies used the last observation carried forward (LOCF) approach for those who left the study (<LINK REF="STD-Klimke-1993" TYPE="STUDY">Klimke 1993</LINK>; <LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK>; <LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>), which is prone to bias (<LINK REF="REF-Leucht-2007" TYPE="REFERENCE">Leucht 2007</LINK>); other studies only presented completer analyses. This did not affect the results of the review because <LINK REF="STD-Bender-1997" TYPE="STUDY">Bender 1997</LINK> is the only study in the first comparison and for <LINK REF="STD-Klimke-1993" TYPE="STUDY">Klimke 1993</LINK> usable data on efficacy outcomes were not available anyway. These limitations led to low or very low quality judgements in several important outcomes in the summary of findings table.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>The evidence presented here is, to the best of our knowledge, complete. However, one can never be certain whether some additional (unpublished) material exists that was not pooled in the analysis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-02-08 18:29:48 +0000" MODIFIED_BY="[Empty name]">
<P>We are not aware of any other systematic reviews of the effects of perazine in schizophrenia.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. For clinicians</HEADING>
<P>Clinicians should be aware that perazine is an antipsychotic with a very limited dataset concerning the evidence from randomised controlled trials. The available data do not allow a clear judgement on whether it is more or less effective than other currently used antipsychotics. Although perazine is said to be associated with fewer extrapyramidal side-effects than high-potency conventional antipsychotics, the necessary information could not be extracted from the few randomised controlled trials that are available. However, in three small trials perazine was not associated with more extrapyramidal side-effects than zotepine and amisulpride. Therefore perazine might have a similar risk for movement disorders as these second-generation antipsychotics, but larger trials are needed to confirm this hypothesis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. For people with schizophrenia</HEADING>
<P>People with schizophrenia should be aware that although German and Polish psychiatrists have more than 30 years experience of treating patients with perazine, there exists only very limited evidence from randomised controlled trials on its effectiveness and its tolerability.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. For managers, founders, decision makers</HEADING>
<P>They should be aware that perazine is a cheap antipsychotic which possibly has atypical properties (low extrapyramidal symptom risk) and that it is worth examining perazine in randomised trials. Indeed, the most recent randomised controlled trial found no major difference in efficacy and numbers leaving the study early between perazine and olanzapine or ziprasidone (<LINK REF="STD-Tybura-2012" TYPE="STUDY">Tybura 2012</LINK>).</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>The trials that were reviewed predated the CONSORT statement (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>). Had this been anticipated more data may have been available to inform practice. However, even with better reporting of the trials, the possibility of drawing firm conclusions would have been limited due to the low number of participants that were included (479). Since there seems to be an indication that perazine might have similar properties to some of the newer second-generation antipsychotics, in terms of movement disorders, further well-designed studies are called for. See also <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank the team of the Cochrane Schizophrenia Group for all the help they gave us concerning the literature search and for their helpful comments on this review. We would also like to thank Jerzy Samochowiec and Promonta Lundbeck Hamburg for their information on perazine trials and for sending us a full report (Jerzy Samochowiec) and abstracts and congress posters which we would otherwise not have obtained.</P>
<P>The Cochrane Schizophrenia Group produces and maintains a template for the methods section, we have used this template and adapted it as required.</P>
<P>The search term and searches for the 2012 update were developed and carried out by the Trial Search Co-ordinator of the Cochrane Schizophrenia Group, Samantha Robers.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Stefan Leucht: has received honoraria for lectures from Abbvie, Astra Zeneca, Bristol-Myers Squibb, ICON, Eli Lilly, Janssen, Johnson &amp; Johnson, Roche, SanofiAventis, Lundbeck and Pfizer; honoraria for consulting and advisory boards from Roche, Eli Lilly, Medavante, Bristol-Myers Squibb, Alkermes, Janssen, Johnson &amp; Johnson and Lundbeck. Eli Lilly has provided medication for a study with SL as primary investigator.</P>
<P>Markus Dold: nothing to declare.</P>
<P>Bartosz Helfer: nothing to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Stefan Leucht: protocol development, literature search, data extraction, updating, writing of the review.</P>
<P>Benno Hartung: protocol development, literature search, data extraction.</P>
<P>Bartosz Helfer: updating, study extraction, writing of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-12-11 10:00:54 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-12-11 10:00:12 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-12-11 09:59:24 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bender-1997" MODIFIED="2013-12-11 09:58:52 +0000" MODIFIED_BY="[Empty name]" NAME="Bender 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bender S, Olbrich H, Hornstein C, Schöne W, Falkai P, Trimipramine Study Group</AU>
<TI>Antipsychotic efficacy of the antidepressant trimipramine: double-blind comparison with the phenothiazine perazine</TI>
<SO>6th World Congress of Biological Psychiatry</SO>
<YR>June 22-27 1997</YR>
<CY>Nice, France</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75029586"/>
<IDENTIFIER TYPE="OTHER" VALUE="PMID 4608707"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bender S, Olbrich H, Hornstein C, Schöne W, Falkai P</AU>
<TI>Antipsychotic efficacy of trimipramine: double-blind comparison with a classical neuroleptic</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>5</NO>
<PG>151</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-11 09:58:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bender S, Olbrich HM, Fischer W, Hornstein C, Schoene W, Falkai P, et al</AU>
<TI>Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double-blind comparison with the phenothiazine perazine</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2003</YR>
<VL>36</VL>
<NO>2</NO>
<PG>61-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE: 2003210869"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blaeser-Kiel G</AU>
<TI>Schizoaffective disorders - testing of antipsychotic components of trimipramine</TI>
<TO>Schizoaffektive Störungen. Antipsychotische Komponente von Trimipramin im Test</TO>
<SO>TW Neurologie Psychiatrie</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>10</NO>
<PG>780-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dieterle-1991" MODIFIED="2013-12-11 09:58:59 +0000" MODIFIED_BY="[Empty name]" NAME="Dieterle 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Ackenheil M, Dieterle D, Kapfhammer HP, Müller-Spahn F, Hippius H</AU>
<TI>not available</TI>
<TO>Therapievergleich von Perazin und Zotepin bei schizophrenen Patienten</TO>
<SO>Therapie mit Neuroleptika - Perazin</SO>
<YR>1988</YR>
<PG>60-4</PG>
<ED>Helmchen H, Hippius H, Tölle R</ED>
<PB>Thieme Verlag</PB>
<CY>Stuttgart, New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-11 09:58:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dieterle DM, Albus M, Blanke E, Eben E, Klein H, Müller-Spahn, Rüther E</AU>
<TI>A double-blind comparison of aminosultoprid (Dan 2163) versus perazine in schizophrenic patients</TI>
<SO>4th World Congress of Biological Psychiatry; 1989 Sept 8-13; Philadelphia, USA</SO>
<YR>1989</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-07 17:24:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dieterle DM, Albus M, Blanke E, Eben E, Klein H, Mullerspahn F, et al</AU>
<TI>A double-blind comparison of aminosultoprid (dan 2163) versus perazine in schizophrenic-patients</TI>
<SO>International Journal of Neuroscience</SO>
<YR>1987</YR>
<VL>32</VL>
<NO>1-2</NO>
<PG>438</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-07 02:29:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dieterle DM, Müller-Spahn F, Ackenheil M</AU>
<TI>Comparison of zotepine and perazine in schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>1988</YR>
<VL>96 Suppl 1</VL>
<PG>340</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-07 02:29:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dieterle DM, Müller-Spahn F, Ackenheil M</AU>
<TI>Efficacy and tolerance of zotepine in a double-blind comparison with perazine in schizophrenics</TI>
<TO>Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten</TO>
<SO>Fortschritte der Neurologie und Psychiatrie</SO>
<YR>1991</YR>
<VL>59 Suppl 1</VL>
<PG>18-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Müller-Spahn F, Dieterle D, Ackenheil M</AU>
<TI>Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms: results of an open and a double-blind controlled study</TI>
<TO>Klinische Wirksamkeit von Zotepin in der Behandlung schizophrener Minussymptomatik: Ergebnisse einer offenen und einer doppelblind-kontrollierten Studie</TO>
<SO>Fortschritte der Neurologie und Psychiatrie</SO>
<YR>1991</YR>
<VL>59</VL>
<PG>30-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klimke-1993" NAME="Klimke 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klimke A, Klieser E, Lehmann E, Miele L</AU>
<TI>Initial improvement as a criterion for drug choice in acute schizophrenia</TI>
<TO>Frühes Ansprechen als Kriterium der Medikamentenwahl bei akuter Schizophrenie</TO>
<SO>Pharmacopsychiatry</SO>
<YR>1993</YR>
<VL>26</VL>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klimke A, Klieser E</AU>
<TI>Clinical relevance of the test dose model for drug choice and response in acute schizophrenia</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1992</YR>
<VL>25</VL>
<PG>85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-R_x00fc_ther-1988" NAME="Rüther 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Rüther E, Blanke J</AU>
<TI>not available</TI>
<TO>Therapievergkeich von Aminosultoprid (DAN 2163) und Perazin bei schizophrenen Patienten</TO>
<SO>Therapie mit Neuroleptika - Perazin</SO>
<YR>1988</YR>
<PG>65-70</PG>
<ED>Helmchen H, Hippius H, Tölle R</ED>
<PB>Thieme Verlag</PB>
<CY>Stuttgart, New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1982" MODIFIED="2012-09-01 07:51:32 +0100" MODIFIED_BY="[Empty name]" NAME="Schmidt 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Küstner U, Renfordt E, Müller-Oerlinghausen B</AU>
<TI>Relationship between neuroleptic medication, handwriting area and therapeutic response</TI>
<SO>Proceedings of the 14. CINP-Congress, Florence</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meya U, Renfordt E</AU>
<TI>Can changes in eye-contacts predict therapeutic outcome in schizophrenic patients undergoing neuroleptic treatment?</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1986</YR>
<VL>19</VL>
<PG>429-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Renfordt E, Küstner U, Müller-Oerlinghausen B</AU>
<TI>not available</TI>
<TO>Handschriftveränderungen unter Perazin und Haloperidol</TO>
<SO>Therapie mit Neuroleptika - Perazin</SO>
<YR>1988</YR>
<PG>55-60</PG>
<ED>Helmchen H, Hippius H, Tölle R</ED>
<PB>Thieme-Verlag</PB>
<CY>Stuttgart, New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Schüssler G, Müller-Oerlinghausen B, Schmidt LG</AU>
<TI>not available</TI>
<TO>Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten</TO>
<SO>Therapie mit Neuroleptika - Perazin</SO>
<YR>1988</YR>
<PG>40-50</PG>
<PB>Thieme-Verlag</PB>
<CY>Stuttgart, New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-01 07:51:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt LG, Schüssler G, Kappes C-V, Müller-Oerlinghausen B</AU>
<TI>A double-blind trial of 2 oral neuroleptics (perazine vs. haloperidol) in different dosages for acute schizophrenic patients</TI>
<TO>Vergleich einer höher dosierten Haloperidol-Therapie mit einer Perazin-Standard-Therapie bei akut schizophrenen Patienten</TO>
<SO>Nervenarzt</SO>
<YR>1982</YR>
<VL>53</VL>
<NO>9</NO>
<PG>530-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt LG, Schüssler G, Kappes V, Mühlbauer H, Müller-Oerlinghausen B</AU>
<TI>A double-blind comparison of the antipsychotic efficacy of perazine compared to haloperidol</TI>
<TO>Doppelblind-Studie zur antipsychotischen Wirkung von Perazin verglichen mit Haloperidol</TO>
<SO>Arzneimittel-Forschung</SO>
<YR>1982</YR>
<VL>32</VL>
<NO>8</NO>
<PG>910</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tybura-2012" MODIFIED="2013-12-11 09:59:14 +0000" MODIFIED_BY="[Empty name]" NAME="Tybura 2012" YEAR="2009">
<REFERENCE MODIFIED="2013-02-17 10:34:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Samochowiec J, Tybura P, Wysiecka JP</AU>
<TI>Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-11 09:59:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tybura P, Samochowiec A, Beszlej A, Grzywacz A, Mak M, Frydecka D, et al</AU>
<TI>Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients</TI>
<SO>Pharmacological Reports</SO>
<YR>2012</YR>
<VL>64</VL>
<PG>528-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetzel-1991" MODIFIED="2013-12-11 09:59:24 +0000" MODIFIED_BY="[Empty name]" NAME="Wetzel 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-12-11 09:59:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wetzel H, Bardeleben U, Holsboer F, Benkert O</AU>
<TI>Zotepine versus perazine in paranoid schizophrenia: a double-blind controlled trial of antipsychotic efficacy</TI>
<TO>Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppeltblind-kontrollierte Wirksamkeitsprüfung</TO>
<SO>Fortschritte der Neurologie und Psychiatrie</SO>
<YR>1991</YR>
<VL>59 Suppl 1</VL>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-12-11 10:00:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bender-1999" MODIFIED="2013-12-11 09:59:32 +0000" MODIFIED_BY="[Empty name]" NAME="Bender 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-11 09:59:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bender S, Czekalla J, Hille S, Schlömer T, Schlebusch A, Gastpar M</AU>
<TI>Evaluation of dry mouth and its treatment in the course of antipsychotic pharmacotherapy</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9 Suppl 5</VL>
<PG>293</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Czekalla-1999" MODIFIED="2013-12-11 09:59:42 +0000" MODIFIED_BY="[Empty name]" NAME="Czekalla 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-11 09:59:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Czekalla J, Bender S, Dittmann RW, Gastpar M</AU>
<TI>Effect of olanzapine on salivation is less prominent than predicted by its in vitro muscarinic binding profile</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9 Suppl 5</VL>
<PG>292-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischer-1992" NAME="Fischer 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischer S, Kissling W, Kuß H-J</AU>
<TI>Schizophrenic patients treated with high dose phenothiazine or thioxanthene become deficient in polyunsaturated fatty acids in their thrombocytes</TI>
<SO>Biochemical Pharmacology</SO>
<YR>1992</YR>
<VL>44</VL>
<NO>2</NO>
<PG>317-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaebel-1981" NAME="Gaebel 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Pietzcker A, Poppenberg A</AU>
<TI>Predictors of the course of schizophrenic diseases under neuroleptic long-term medication</TI>
<TO>Prädiktoren des Verlaufs schizophrener Erkrankungen unter neuroleptischer Langzeitmedikation</TO>
<SO>Pharmacopsychiatry</SO>
<YR>1981</YR>
<VL>14</VL>
<PG>180-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaebel-1986" NAME="Gaebel 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gaebel W, Oschinsky AM</AU>
<TI>Low-dose neuroleptic treatment in neurotic disorders</TI>
<SO>Abstract book of the the 15. CINP-Congress</SO>
<YR>1986</YR>
<CY>San Juan, Puerto Rico</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaebel-1988" MODIFIED="2013-12-07 02:33:29 +0000" MODIFIED_BY="[Empty name]" NAME="Gaebel 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Pietzcker A, Ulrich G, Schley J, Müller-Oerlinghausen B</AU>
<TI>Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1988</YR>
<VL>21</VL>
<PG>384-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gaebel W, Schley J, Müller-Oerlinghausen B</AU>
<TI>Early pharmacokinetic and clinical data as predictors of response to acute antipsychotic treatment with perazine</TI>
<SO>Abstract book of the 15. CINP-Congress at San Juan, Puerto Rico</SO>
<YR>1986</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-07 02:33:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Schley J, Renfordt E, Müller-Oerlinghausen B</AU>
<TI>Early treatment effects of perazine as predictor of acute antipsychotic treatment outcome in schizophrenics</TI>
<SO>Acta Pharmacolgica Toxicologica</SO>
<YR>1986</YR>
<VL>59 Suppl 5</VL>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaebel-1992" NAME="Gaebel 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaebel W, Wölwer W</AU>
<TI>Facial expression and emotional face recognition in schizophrenia and depression</TI>
<SO>Psychiatry and Clinical Neuroscience</SO>
<YR>1992</YR>
<VL>242</VL>
<PG>46-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerson-1964" MODIFIED="2013-02-08 09:16:48 +0000" MODIFIED_BY="[Empty name]" NAME="Gerson 1964" YEAR="1964">
<REFERENCE MODIFIED="2013-02-08 09:16:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gerson IM, Chat E, Twigger NA</AU>
<TI>Clinical trial of a potentiated diketopiperazine derivative as a psychopharmacological agent for the treatment of psychotic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1964</YR>
<VL>121</VL>
<PG>179-81</PG>
<CY>UNITED STATES</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14196596"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grabe-1999" NAME="Grabe 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grabe HJ, Wolf T, Grätz S, Laux G</AU>
<TI>The influence of clozapine and typical neuroleptics on information processing of the central nervous sstem under cinical conditions in schizophrenic disorders: implications for fitness to drive</TI>
<SO>Neuropsychobiology</SO>
<YR>1999</YR>
<VL>40</VL>
<PG>196-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarema-1999" MODIFIED="2013-12-11 09:59:55 +0000" MODIFIED_BY="[Empty name]" NAME="Jarema 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-11 09:59:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarema M, Konieczynska Z</AU>
<TI>Quality of life of schizophrenic patients treated with classic and "old" atypical neuroleptics</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9 Suppl 5</VL>
<PG>269</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jockers_x002d_Scher_x00fc_bl1997" NAME="Jockers-Scherübl1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jockers-Scherübl MC, Godemann F, Pietzcker A</AU>
<TI>Paroxetine augmentation of neuroleptic treatment in chronic schizophrenia: An open pilot study</TI>
<SO>Proceedings of the 20th Symposium of the AGNP, Nürnberg</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kemperdick-1967" MODIFIED="2013-12-07 02:34:31 +0000" MODIFIED_BY="[Empty name]" NAME="Kemperdick 1967" YEAR="1967">
<REFERENCE MODIFIED="2013-12-07 02:34:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kemperdick KT, Nieling C, Steinig A</AU>
<TI>not available</TI>
<TO>Behandlung schizophrener Psychosen mit schwach potenten Neuroleptika</TO>
<SO>Medizinische Klinik</SO>
<YR>1967</YR>
<VL>62</VL>
<PG>1512-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuhs-1988" NAME="Kuhs 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Kuhs H, Eikelmann B</AU>
<TI>not available</TI>
<SO>Therapie mit Neuroleptika-Perazin</SO>
<YR>1988</YR>
<PG>51-6</PG>
<ED>Helmchen H, Hippius H, Tölle R</ED>
<PB>Thieme-Verlag</PB>
<CY>Stuttgart, New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loza-2001" NAME="Loza 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loza B, Kucharska-Pietura K, Debowska G</AU>
<TI>Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on wcst and dichotic listening scores</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>285</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2103#"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazurek I, Loza B, Lecyk A</AU>
<TI>Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S347</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P.2.156"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohlmeier-2007" MODIFIED="2013-02-08 09:21:46 +0000" MODIFIED_BY="[Empty name]" NAME="Ohlmeier 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-08 09:21:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohlmeier MD, Jahn K, Wilhelm-Gossling C, Godecke-Koch T, Hoffmann J, Seifert J, et al</AU>
<TI>Perazine and carbamazepine in comparison to olanzapine in schizophrenia</TI>
<SO>Neuropsychobiology</SO>
<YR>2007</YR>
<VL>55</VL>
<NO>2</NO>
<PG>81-8</PG>
<CY>Switzerland</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17570951"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pietzcker-1981" NAME="Pietzcker 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pietzcker A, Poppenberg A, Schley J, Müller-Oerlinghausen B</AU>
<TI>Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug</TI>
<SO>Archives of Psychiatry and Neurological Sciences</SO>
<YR>1981</YR>
<VL>229</VL>
<PG>315-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pietzcker-1984" NAME="Pietzcker 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pietzcker A, Müller-Oerlinghausen B</AU>
<TI>The outpatient clinic for patients under chronic lithium treatment as a phase-IV research tool</TI>
<TO>Katamnesen für Patienten unter Lithium- und Neuroleptikabehandlung als Forschungshilfsinstrument in der Phase IV der Arzneimittelforschung</TO>
<SO>Pharmacopsychiatry</SO>
<YR>1984</YR>
<VL>17</VL>
<PG>162-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rein-1983" NAME="Rein 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rein W, Schied HW, Breyer-Pfaff U, Straube E</AU>
<TI>Prediction and evaluation criteria in perazine therapy of acute schizophrenics: Methodological considerations, sample population, and research variables</TI>
<TO>Prädiktion und Verlaufsbeurteilung bei Perazin-Therapie akut Schizophrener: Methodologische Überlegungen, Patientengut und Untersuchungsvariable</TO>
<SO>Pharmacopsychiatry</SO>
<YR>1983</YR>
<VL>16</VL>
<PG>147-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schied-1983" NAME="Schied 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schied HW, Rein W, Straube E, Jung H, Breyer-Pfaff U</AU>
<TI>Prediction and evaluation criteria in perazine therapy of acute schizophrenics: psychopathological results</TI>
<TO>Prädiktion und Verlaufsbeurteilung bei Perazin-Therapie akut Schizophrener: Psychopathologische Ergebnisse</TO>
<SO>Pharmacopsychiatry</SO>
<YR>1983</YR>
<VL>16</VL>
<PG>152-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1988" NAME="Schmidt 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt LG, Siemetzki H</AU>
<TI>Assessment of neuroleptic therapy in schizophrenic patients admitted to a university psychiatric department</TI>
<TO>Differentielle Wirkprofile der neuroleptischen Therapie akut Schizophrener</TO>
<SO>Nervenarzt</SO>
<YR>1988</YR>
<VL>59</VL>
<PG>721-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terminska-1989" NAME="Terminska 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terminska K, Mrowiec W</AU>
<TI>Comparison of influence of perazine, fluphenazine, trifluoroperazine, chloropromazine and haloperidol on primary and deficit schizophrenic symptoms in patients first hospitalized because of paranoid schizophrenia</TI>
<TO>Badanie Porownawcze Wplywu Perazyny, Flufenazyny, Trifluoroperazyny, Chloropramazyny I Haloperidolu Na Objawy Pierwotne I Deficytowe Pierwszego Zachorowania Na Schizofrenie Paranoidalna</TO>
<SO>Psychatria Polska</SO>
<YR>1989</YR>
<VL>23</VL>
<NO>1</NO>
<PG>24-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volz-1994" MODIFIED="2013-12-11 10:00:12 +0000" MODIFIED_BY="[Empty name]" NAME="Volz 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-12-11 10:00:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volz HP, Mackert A, Diefenbacher A, Friedrich A, Gaebel W, Müller H, et al</AU>
<TI>Orthostatic challenge during neuroleptic test dose: A possible predictor of short-term outcome</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1994</YR>
<VL>30</VL>
<NO>2-3</NO>
<PG>94-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetterling-1996" NAME="Wetterling 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetterling T, Müßigbrodt H</AU>
<TI>not available</TI>
<TO>Gewichtszunahme: eine Nebenwirkung von Zotepin (Nipolept)?</TO>
<SO>Nervenarzt</SO>
<YR>1996</YR>
<VL>67</VL>
<PG>256-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetzel--1991" NAME="Wetzel  1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetzel H, Wiedemann K, Holsboer F, Benkert O</AU>
<TI>Savoxepine: Invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with acute schizophrenic patients</TI>
<SO>Psychopharmacology</SO>
<YR>1991</YR>
<VL>103</VL>
<NO>2</NO>
<PG>280-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-02-17 10:34:59 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-12-11 10:00:54 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-12-11 10:00:54 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alderson-2004" MODIFIED="2012-07-06 10:50:09 +0100" MODIFIED_BY="[Empty name]" NAME="Alderson 2004" TYPE="OTHER">
<AU>Alderson P, Green S, Higgins JPT</AU>
<TI>Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]</TI>
<SO>The Cochrane Library</SO>
<YR>2004</YR>
<NO>Issue 1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley &amp;amp; Sons, Ltd."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PER170800"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2013-12-11 10:00:24 +0000" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials. The CONSORT Statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benkert-1996" NAME="Benkert 1996" TYPE="BOOK">
<AU>Benkert O, Hippius H</AU>
<SO>Psychiatrische Pharmakotherapie</SO>
<YR>1996</YR>
<EN>6th</EN>
<PB>Springer Verlag</PB>
<CY>Berlin</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<TO>Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite</TO>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2012-07-10 13:25:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10667106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" MODIFIED="2012-10-19 09:22:30 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davey-Smith-1998" MODIFIED="2012-10-19 08:43:58 +0100" MODIFIED_BY="[Empty name]" NAME="Davey Smith 1998" TYPE="JOURNAL_ARTICLE">
<AU>Davey Smith G, Egger M</AU>
<TI>Meta-analysis: Unresolved issues and future developments</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>221-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town</SO>
<YR>2000</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2005" MODIFIED="2012-07-06 10:51:39 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2005" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>John Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-07-06 10:51:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-06 10:51:39 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Endicott-1976" NAME="Endicott 1976" TYPE="JOURNAL_ARTICLE">
<AU>Endicott J, Spitzer RL, Fleiss JL, Cohen J</AU>
<TI>The Global Assessment Scale</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1976</YR>
<VL>33</VL>
<PG>766-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enss-1958" NAME="Enss 1958" TYPE="JOURNAL_ARTICLE">
<AU>Enss H, Hartmann K, Richter H-E</AU>
<TI>not available</TI>
<TO>Klinische Erfahrungen mit einem neuen Piperazin-Derivat des Phenothiazins in der Neuro-Psychiatrie</TO>
<SO>Archiv für Neurologie und Nervenkrankheiten</SO>
<YR>1958</YR>
<VL>197</VL>
<PG>534</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>7</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grohmann-1988" NAME="Grohmann 1988" TYPE="BOOK_SECTION">
<AU>Grohmann R, Koch R, Rüther E, Schmidt LG</AU>
<TI>not available</TI>
<TO>Nebenwirkungen von Perazin im Vergleich zu anderen Neuroleptika</TO>
<SO>Therapie mit Neuroleptika - Perazin</SO>
<YR>1988</YR>
<PG>74-83</PG>
<ED>Helmchen H, Hippius H, Tölle R</ED>
<PB>Georg Thieme Verlag</PB>
<CY>Stuttgart/New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK_SECTION">
<AU>Guy W, Bonato RR</AU>
<TI>Clinical Global Impressions</TI>
<SO>Manual for the ECDEU Assessment Battery, 2. Rev ed</SO>
<YR>1970</YR>
<PB>National Institute of Mental Health</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-07-10 13:27:37 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hippius-1962" NAME="Hippius 1962" TYPE="CONFERENCE_PROC">
<AU>Hippius H</AU>
<TI>Long-term pharmacotherapy of schizophrenia</TI>
<SO>Proceedings of the II International Conference of the Manfred Sakel Foundation</SO>
<YR>1962</YR>
<PB>CC Page and Co</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2009" MODIFIED="2013-12-11 10:00:40 +0000" MODIFIED_BY="[Empty name]" NAME="Hutton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hutton JL</AU>
<TI>Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials</TI>
<SO>British journal of haematology</SO>
<YR>2009</YR>
<VL>146</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carrol D, Jenkinson C, Reynolds DJM, Gavanagh DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomised controlled trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kr_x00fc_ger-1963" NAME="Krüger 1963" TYPE="JOURNAL_ARTICLE">
<AU>Krüger HJ, Schwarz H</AU>
<TI>not available</TI>
<TO>Neue Aspekte der psychiatrischen Langzeittherapie in der psychiatrischen Ambulanz und Klinik</TO>
<SO>Medizinische Welt</SO>
<YR>1963</YR>
<VL>9</VL>
<PG>463-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2012-07-10 13:25:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15982856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of brief psychiatric rating scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2012-07-10 13:25:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16199797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Engel RR, Bauml J, Davis JM</AU>
<TI>Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>183-91</PG>
<IDENTIFIERS MODIFIED="2012-07-10 13:25:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16905632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2012-10-19 09:23:35 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marwaha S, Johnson S</AU>
<TI>Schizophrenia and employment? A review</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>224</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Menge-1988" NAME="Menge 1988" TYPE="BOOK_SECTION">
<AU>Menge HG, Brand U</AU>
<TI>not available</TI>
<TO>Pharmakologie von Perazin und seinen Hauptmetaboliten</TO>
<SO>Therapie mit Neuroleptika - Perazin</SO>
<YR>1988</YR>
<PG>9-13</PG>
<ED>Helmchen H, Hippius H, Tölle R</ED>
<PB>Georg Thieme Verlag</PB>
<CY>Stuttgart/New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2013-12-11 10:00:54 +0000" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seeman-1981" NAME="Seeman 1981" TYPE="JOURNAL_ARTICLE">
<AU>Seeman P</AU>
<TI>Brain dopamine receptors</TI>
<SO>Pharmacological Review</SO>
<YR>1981</YR>
<VL>32</VL>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1978" MODIFIED="2012-10-19 09:24:33 +0100" MODIFIED_BY="[Empty name]" NAME="Tsuang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MT</AU>
<TI>Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>153-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2012-07-10 13:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>7</NO>
<PG>254-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bender-1997">
<CHAR_METHODS>
<P>Allocation: randomised - chronological randomisation using a validated computer program where eligible patients were assigned to the lowest yet unassigned treatment number available at the study centre.<BR/>Blindness: double - identical capsules.<BR/>Duration: 35 days.<BR/>Raters: not stated to be independent of treatment.<BR/>Design: multi-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizophreniform disorder (DSM-III-R), BPRS &gt; 39.<BR/>N = 95.<BR/>Sex: not indicated.<BR/>Age: between 18 and 70 years.<BR/>History: not indicated.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-07 09:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Perazine: dose average 459 mg/day SD 62 mg/day. N = 50.<BR/>2. Trimipramine: dose average 309 mg/day SD 73 mg/day. N = 45.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Improvement of global state.<BR/>Leaving the study early.<BR/>Mental state: BPRS.<BR/>Adverse events: EPS (participants with at least one movement disorder, at least one dose of antiparkinson medication).<BR/>Adverse events: number of patients with at least one adverse event.</P>
<P>Unable to use - <BR/>Mental state: Depression scale (unclear N).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>We considered trimipramine - a tricyclic antidepressant - to be an active placebo.<BR/>Jadad = 5</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dieterle-1991">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blindness: double - identical capsules.<BR/>Duration: 28 days.<BR/>Raters: not stated to be independent of treatment.<BR/>Design: single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-07 09:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (ICD-9).<BR/>Excluded: substance dependence, epilepsy, neurological diseases, hypotension, history of adverse events.<BR/>N = 40.<BR/>Sex: 27F, 13M.<BR/>Age: mean ~ 33 years (range: 20-64).<BR/>History: 16 participants were hospitalised for the first time.<BR/>Setting: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-07 09:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Perazine: dose mean 350 mg/frequency not reported (SD 100, range 75-675). N = 20.<BR/>2. Zotepine: dose mean 240 mg/frequency not reported (SD 70, range 50-450). N = 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Mental state: BPRS.<BR/>Adverse effects: vegetative side-effects.</P>
<P>Unable to use -<BR/>Global state: CGI (only P value).<BR/>Mental state: SANS, AMDP (only P value).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klimke-1993">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blindness: double - no further details.<BR/>Duration: 28 days.<BR/>Raters: not stated to be independent from treatment.<BR/>Design: single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-07 09:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: acute schizophrenia (ICD-9) without antipsychotic treatment at admission.<BR/>N = 50.<BR/>Sex: 21M, 29F.<BR/>Age: mean 36.6 years (SD 11.9, range 20-62).<BR/>History: duration since first episode: 80.4 months (SD 104.4, range 0-400).<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>All patients were treated with 15 mg haloperidol intravenously for the first three days; then random assignment to:</P>
<P>1. Perazine: dose 300 mg/day. N = 25.<BR/>2. Haloperidol: dose 15 mg/day. N = 25.</P>
<P>Flunitrazepam (2 mg) and biperiden (1-2 times 5 mg) were allowed as concomitant medication.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Mental state: BPRS.</P>
<P>Unable to use -<BR/>Global state: CGI (only P value).<BR/>Adverse effects: SAS (only P value).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-R_x00fc_ther-1988">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blindness: double - no further details.<BR/>Duration: 28 days.<BR/>Raters: not stated to be independent of treatment.<BR/>Design: single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (-like) disorders (ICD 9 295.1-295.7); 'acutely ill', pretreatment with antipsychotics was allowed.<BR/>N = 30.<BR/>Sex: 14M, 16F.<BR/>Age ~ 35 years.<BR/>History: 13 were first episode patients.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-07 09:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Perazine: dose starting at 400 mg/day (max. 1000 mg/day). N = 15.<BR/>2. Aminosultoprid: dose starting at 400 mg/day (max. 1000 mg/day). N = 15.</P>
<P>Allowed additional medication: chloraldurat (sleep medication), diazepam and biperiden (antiparkinson medication).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS.<BR/>Global state: CGI.<BR/>Vital signs.<BR/>Laboratory.</P>
<P>Unable to use -<BR/>Mental state: NGI, AMDP (no mean or no SD).<BR/>Adverse effects: SAS, Webster Scale (no mean or no SD).<BR/>Laboratory: most laboratory data (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmidt-1982">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blindness: double - HPL tablets + placebo liquid or perazine liquid + placebo tablets.<BR/>Duration: 28 days.<BR/>Raters: not stated to be independent of treatment.<BR/>Design: single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-07 09:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: acute paranoid schizophrenia (ICD 9 295.3).<BR/>Excluded: catatonic, schizoaffective and residual patients.<BR/>N = 32.<BR/>Sex: all male.<BR/>Age: ~ 31 years.<BR/>History: duration ill ~ 4 years, ~ 3 previous admissions.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-07 09:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Perazine: dose 300, 600 or 900 mg/day according to clinical requirements. N = 17.<BR/>2. Haloperidol: dose 15, 30 or 45 mg/day according to clinical requirements. N = 15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Global state: CGI.<BR/>Adverse effects: number of EPS, dry mouth, tiredness, increase of transaminases, neuroleptic malignant syndrome.</P>
<P>Unable to use -<BR/>Mental state: AMDP (no SD).<BR/>Adverse effects: laboratory results (only P values), EWL, SAS (no SD or no mean).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>20 screened patients could not be randomised because they were too severely ill.<BR/>Jadad = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tybura-2012">
<CHAR_METHODS MODIFIED="2013-02-17 10:54:56 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, allocation concealed (see below).<BR/>Blindness: open.<BR/>Duration: 3 months.<BR/>Raters: not stated to be independent of treatment.<BR/>Design: two-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: paranoid schizophrenia according to "Composite International Diagnostic Interview" and ICD-10.<BR/>Excluded: serious neurological and/or somatic disorders (e.g. stroke, hepatic insufficiency, diabetes).<BR/>N = 191.<BR/>Sex: 89 men 102 women.<BR/>Age: ~ 36 years.<BR/>History: duration ill ~ 10 years.<BR/>Setting: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-07 09:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Perazine 300-600mg/day. N = 60.</P>
<P>2. Olanzapine 10-20mg/day. N = 72.</P>
<P>3. Ziprasidone 120-160mg/day. N = 59.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-03 15:19:25 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>General mental state: percentage PANSS change from baseline.</P>
<P>No further outcomes were reported, the main focus of the study was genetics.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-17 10:53:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Can you Add that you have not calculated the Jadad score for Tybura 2012. It makes it look missed out rather than not calculated. Can you correct the 33.3 from 33,3 &lt;/p&gt;" NOTES_MODIFIED="2013-02-17 10:53:54 +0000" NOTES_MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-07 02:17:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wetzel-1991">
<CHAR_METHODS>
<P>Allocation: randomised - no further details.<BR/>Blindness: double - no further details.<BR/>Raters: not stated to be independent of treatment.<BR/>Design: single-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-07 02:17:54 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia 'with positive symptoms' (ICD-9).<BR/>Excluded: people with substance dependence, epilepsy, pregnancy, organic psychoses, relevant other diseases or people currently treatment with depot antipsychotics.<BR/>N = 41.<BR/>Sex: 16M, 25F.<BR/>Age: mean ~ 40 years.<BR/>History: not indicated.<BR/>Setting: hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-07 09:49:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Perazine: dose starting at 50 mg/day then flexible dose (max. 900 mg/day). N = 21.<BR/>2. Zotepine: dose starting at 100 mg/day, then flexible dose (max. 600 mg/day). N = 20.</P>
<P>Chloralhydrate (sleep medication), flurazepam, diazepam and biperiden (anticholinergic) were allowed as concomitant medication.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Global state: GAS.<BR/>Mental state: BPRS.<BR/>Extrapyramidal side effects.<BR/>Vital signs: EEG, ECG, laboratory.</P>
<P>Unable to use -<BR/>Mental state: AMDP, FSCL-NL, FSUCL (no mean or no SD, or no usable data). <BR/>Global state: CGI (no usable data). <BR/>Adverse effects: AIMS, Gerlach scale (no mean or no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Jadad = 3</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>General abbreviations:<BR/>HPL = haloperidol<BR/>EPS = extrapyramidal side-effects.<BR/>M = males<BR/>F = females<BR/>N = number<BR/>mg = milligram<BR/>SD = standard deviation<BR/>ECG = electrocardiogram<BR/>EEG = electroencephalogram</P>
<P>Diagnostic tools:<BR/>DSM-III-R = Diagnostic and Statistical Manual of Mental disorders, third edition, revised<BR/>ICD-9 = International Classification of Diseases, ninth revision</P>
<P>Global effect scales:<BR/>CGI = Clinical Global Impression (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>GAS = Global Assessment of Symptoms Scale (<LINK REF="REF-Endicott-1976" TYPE="REFERENCE">Endicott 1976</LINK>)</P>
<P>Mental state scales:<BR/>AMDP = Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (AMDP 1981)<BR/>BPRS = Brief Psychiatric Rating Scale (Overall and Gorham 1970)<BR/>FSCL-NL = Collegium Internationale Psychiatricae Scalarum, CIPS 1986<BR/>FSUCL = Collegium Internationale Psychiatricae Scalarum, CIPS 1986<BR/>SANS = Scale for Assessment of Negative Symptoms (Andreasen 1989)</P>
<P>Adverse effects scales:<BR/>AIMS = Abnormal Involuntary Movement Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>EWL = Eigenschaftswörterliste (Janke 1977)<BR/>Gerlach Scale (Gerlach 1983)<BR/>NGI = (no reference)<BR/>SAS = Simpson and Angus Scale (Simpson and Angus 1970)<BR/>Webster Scale (no reference)</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bender-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Czekalla-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fischer-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gaebel-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gaebel-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: patients with neurotic instead of schizophrenic disorders.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gaebel-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gaebel-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: patients with schizophrenia and depressive disorders.<BR/>Interventions: perazine versus haloperidol.<BR/>Outcomes: no data for the patients with schizophrenia only; patients with depression are compared with patients with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-08 09:17:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerson-1964">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-08 09:17:15 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grabe-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jarema-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: patients with schizophrenic disorders.<BR/>Interventions: conventional versus 'old' atypical neuroleptics, one of the latter being perazine.<BR/>Outcomes: no data on the patients treated with perazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jockers_x002d_Scher_x00fc_bl1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kemperdick-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kuhs-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Loza-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: patients with schizophrenia.<BR/>Interventions: various atypical antipsychotics versus various typical antipsychotics (among them perazine).<BR/>Outcomes: data for the patients treated with perazine have not been presented separately.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-08 09:23:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohlmeier-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-08 09:23:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia.</P>
<P>Interventions: Perazine combined with carbamazepine versus olanzapine, i.e. no appropriate intervention group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pietzcker-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pietzcker-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rein-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schied-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schmidt-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Terminska-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Volz-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wetterling-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wetzel--1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-02-17 10:34:59 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-11-15 17:27:41 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-01 11:26:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bender-1997">
<DESCRIPTION>
<P>"randomized" (p.61); "A randomization schedule was produced by a validated computer program" (p.63)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-01 11:42:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dieterle-1991">
<DESCRIPTION>
<P>"randomised" (p18)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-01 11:55:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klimke-1993">
<DESCRIPTION>
<P>"randomly assigned" (p.25)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:21:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-R_x00fc_ther-1988">
<DESCRIPTION>
<P>"zufällige Zuteilung" (p.65)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:20:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1982">
<DESCRIPTION>
<P>"Randomisiert" (p.531)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-15 17:27:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tybura-2012">
<DESCRIPTION>
<P>Personal communication from Jerzy Samochowiec: "Both recruiting centers had a simple program generating random allocations. The program was writen by our statistician (P.M.) and allowed random allocation of each patient meeting the study criteria. The program was a simple randomization tool, i.e. it allowed random (with a probability of 33,3%) allocation of each qualified patient to one of three treatment groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-01 12:13:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wetzel-1991">
<DESCRIPTION>
<P>randomized ("Zufallsprinzip") (p.24)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-06-03 15:22:32 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:22:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bender-1997">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:22:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dieterle-1991">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:22:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klimke-1993">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:20:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-R_x00fc_ther-1988">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:20:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1982">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-17 10:41:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tybura-2012">
<DESCRIPTION>
<P>Personal communication from Jerzy Samochowiec: "The processes of initial qualification and randomization were separated. Senior researchers in each center were asked for a random allocation by physicians willing to qualify a patient to the study. The patient was registered in the study database and allocation to one of the study groups was performed as described above. Database records and randomization was a duty of a senior researcher. Hence, the physician deciding to qualify a patient to the study could not predict to which group the patient will be allocated. The allocation was done by another person and was final. The whole system worked like with two 'randomization centers'."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:19:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wetzel-1991">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-06-03 15:21:41 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-01 11:33:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bender-1997">
<DESCRIPTION>
<P>"double-blind" (p.61); "Study medication was administered in capsules indistinguishable in colour, size, form, smell and consistency" (p.63)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-09-01 11:33:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bender-1997">
<DESCRIPTION>
<P>"double-blind" (p.61); "Study medication was administered in capsules indistinguishable in colour, size, form, smell and consistency" (p.63)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-01 11:44:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieterle-1991">
<DESCRIPTION>
<P>"double blind"; "identical capsules" (p.18)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-09-01 11:45:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieterle-1991">
<DESCRIPTION>
<P>"double blind"; "identical capsules" (p.18)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-01 11:57:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klimke-1993">
<DESCRIPTION>
<P>"double blind" (p.25); "Patients and treating psychiatrists were blind to the treatment conditions" (p.26)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-09-01 11:59:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klimke-1993">
<DESCRIPTION>
<P>"double blind" (p.25); "Patients and treating psychiatrists were blind to the treatment conditions" (p.26)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-03 15:21:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x00fc_ther-1988">
<DESCRIPTION>
<P>"doppelblind" (p.70)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-06-03 15:21:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-R_x00fc_ther-1988">
<DESCRIPTION>
<P>"doppelblind" (p.70)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-17 12:24:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidt-1982">
<DESCRIPTION>
<P>"Doppel-Blind" (p.530)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2012-10-17 12:23:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1982">
<DESCRIPTION>
<P>"Doppel-Blind" (p.530)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-17 10:43:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tybura-2012">
<DESCRIPTION>
<P>"Open study". Lack of blinding would not be so important for objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-02-17 10:42:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tybura-2012">
<DESCRIPTION>
<P>"Open study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-06-03 15:19:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wetzel-1991">
<DESCRIPTION>
<P>"Double blind" (p.23)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-06-03 15:19:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wetzel-1991">
<DESCRIPTION>
<P>"Double blind" (p.23)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bender-1997">
<DESCRIPTION>
<P>"double-blind" (p.61)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bender-1997">
<DESCRIPTION>
<P>"double-blind" (p.61)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-01 11:45:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieterle-1991">
<DESCRIPTION>
<P>"double blind" (p.18)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-09-01 11:45:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dieterle-1991">
<DESCRIPTION>
<P>"double blind" (p.18)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-09-01 11:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klimke-1993">
<DESCRIPTION>
<P>"double blind" (p.25)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-09-01 11:59:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klimke-1993">
<DESCRIPTION>
<P>"double blind" (p.25)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-03 15:21:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x00fc_ther-1988">
<DESCRIPTION>
<P>"doppelblind" (p.70)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-06-03 15:21:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-R_x00fc_ther-1988">
<DESCRIPTION>
<P>"doppelblind" (p.70)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-10-17 12:24:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidt-1982">
<DESCRIPTION>
<P>"Doppel-Blind" (p.530)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2012-10-17 12:24:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmidt-1982">
<DESCRIPTION>
<P>"Doppel-Blind" (p.530)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-17 10:43:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tybura-2012">
<DESCRIPTION>
<P>"Open study". Lack of blinding would not be so important for objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-02-17 10:44:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tybura-2012">
<DESCRIPTION>
<P>"Open study".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-06-03 15:19:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wetzel-1991">
<DESCRIPTION>
<P>"Double blind" (p.23)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-06-03 15:19:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wetzel-1991">
<DESCRIPTION>
<P>"Double blind" (p.23)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-01 11:35:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bender-1997">
<DESCRIPTION>
<P>37% dropout rate, not evenly distributed between groups (13/50 and 19/45)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-01 11:46:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dieterle-1991">
<DESCRIPTION>
<P>50% dropout rate, not evenly distributed (12/20 and 8/20)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-01 12:00:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klimke-1993">
<DESCRIPTION>
<P>40% dropout rate, not evenly distributed (7/25 and 13/25)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-03 15:21:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x00fc_ther-1988">
<DESCRIPTION>
<P>Low dropout rate, evenly distributed between groups (2/15 and 3/15)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-03 15:20:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidt-1982">
<DESCRIPTION>
<P>Low dropout rate, evenly distributed (2/17 and 2/15)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tybura-2012">
<DESCRIPTION>
<P>Dropout rate 24%-32%. Reasons for dropout not indicated. LOCF analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-09-01 14:44:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wetzel-1991">
<DESCRIPTION>
<P>20% dropout rate, not evenly distributed (3/21 and 5/20)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-06-03 15:22:37 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:22:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bender-1997">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:22:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dieterle-1991">
<DESCRIPTION>
<P>No SDs for CGI, SANS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:21:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klimke-1993">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:21:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-R_x00fc_ther-1988">
<DESCRIPTION>
<P>Not all SDs provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:20:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schmidt-1982">
<DESCRIPTION>
<P>Not all SDs provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-17 11:14:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tybura-2012">
<DESCRIPTION>
<P>No indication of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:20:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wetzel-1991">
<DESCRIPTION>
<P>No SDs or mean values provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-06-03 15:22:39 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:22:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bender-1997">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:22:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dieterle-1991">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:21:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klimke-1993">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:21:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-R_x00fc_ther-1988">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:20:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmidt-1982">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-17 11:14:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tybura-2012">
<DESCRIPTION>
<P>No obvious other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 15:20:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wetzel-1991">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-02-17 14:45:35 +0000" MODIFIED_BY="Grade Profiler">Perazine versus placebo for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Perazine versus placebo for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> hospital<BR/>
<B>Intervention:</B> perazine versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Perazine versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Acceptability of treatment</B>
<BR/>Leaving the study early due to any reason<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>422 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>262 per 1000</B>
<BR/>(148 to 464)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.62 </B>
<BR/>(0.35 to 1.1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>95<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state</B>
<BR/>change over time (no better or deterioration)<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>467 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>201 per 1000</B>
<BR/>(107 to 378)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.43 </B>
<BR/>(0.23 to 0.81)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>95<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Overall mental state</B>
<BR/>less than 30% BPRS reduction<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>733 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>601 per 1000</B>
<BR/>(447 to 799)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.61 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>95<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Movement disorders</B>
<BR/>number of participants receiving antiparkinson medication<BR/>Follow-up: mean 5 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
<BR/>(46 to 864)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 4.5 </B>
<BR/>(1.04 to 19.45)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>95<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Overall tolerability</B>
<BR/>Leaving the studies early due to adverse events</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No data available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Satisfaction with care</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No data available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No data available</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of bias: high risk of attrition bias.<BR/>
<SUP>2</SUP> Indirectness: acceptability was measured by the number of participants leaving the studies for any reason which is an indirect measure of acceptability.<BR/>
<SUP>3</SUP> Imprecision: very small number of events.<BR/>
<SUP>4</SUP> Indirectness: movement disorders were measured by the number of participants receiving antiparkinson medication which is an indirect measure of adverse events.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-02-17 14:42:15 +0000" MODIFIED_BY="Grade Profiler">Perazine versus other antipsychotics for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Perazine versus other antipsychotics for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with schizophrenia<BR/>
<B>Settings:</B> mainly hospital<BR/>
<B>Intervention:</B> perazine versus other antipsychotics<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Perazine versus other antipsychotics</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Global state</B>
<BR/>change over time (no better or deterioration)<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>266 per 1000</B>
<BR/>(72 to 994)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.33 </B>
<BR/>(0.36 to 4.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>30<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Overall mental state</B>
<BR/>BPRS endpoint score. Scale from: 0 to 108.<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean overall mental state in the control groups was<BR/>
<B>BPRS endpoint score</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean overall mental state in the intervention groups was<BR/>
<B>0.4 lower</B>
<BR/>(0.74 to 0.06 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Movement disorders</B>
<BR/>number of participants receiving antiparkinson medication<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>242 per 1000</B>
<BR/>(106 to 552)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.21 </B>
<BR/>(0.53 to 2.76)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>81<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Overall tolerability</B>
<BR/>Leaving the study early due to adverse events<BR/>Follow-up: mean 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>126 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>110 per 1000</B>
<BR/>(51 to 240)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.87 </B>
<BR/>(0.4 to 1.9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>193<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Acceptability of treatment</B>
<BR/>Leaving the studies early due to any reason<BR/>Follow-up: 1-3 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>296 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>288 per 1000</B>
<BR/>(202 to 409)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.68 to 1.38)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>384<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Satisfaction with care</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No data available</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No data available</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of bias: high risk of reporting bias.<BR/>
<SUP>2</SUP> Imprecision: Small number of events.<BR/>
<SUP>3</SUP> Imprecision: Very small population size.<BR/>
<SUP>4</SUP> Indirectness: adverse events were measured by the number of participants receiving antiparkinson medication which is an indirect measure of adverse events.<BR/>
<SUP>5</SUP> Indirectness: acceptability was measured by the number of participants leaving the studies for any reason which is an indirect measure of acceptability.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-10-07 09:49:02 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-10-07 09:49:02 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-06-03 16:00:23 +0100" MODIFIED_BY="[Empty name]">Suggested design of future study</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TH VALIGN="TOP">
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised - clearly described generation of sequence and concealment of allocation.<BR/>Blindness: double - described and tested.<BR/>Duration: 3 months, 12 months open follow-up.</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia with acute exacerbation.<BR/>N = 900.*<BR/>Age: any.<BR/>Gender: both.<BR/>History: any.</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Interventions</P>
</TH>
<TD>
<P>1. Perazine: dose 300-800 mg/day. N = 300.</P>
<P>2. Haloperidol: dose 2-15 mg/day. N = 300.</P>
<P>3. Olanzapine: dose 5-20mg/day. N = 300.</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TD>
<P>Leaving study early (any reason, adverse events, inefficacy).<BR/>Service outcomes: hospitalised, time in hospital, attending out patient clinics.<BR/>Global impression: Number of participants much improved (CGI)**.<BR/>Mental state: PANSS.</P>
<P>Quality of life, subjective well-being.<BR/>Adverse events.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<BR/>
<BR/>** Primary outcome</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-12-11 09:38:29 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-12-11 09:38:08 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Perazine versus placebo</NAME>
<DICH_OUTCOME CHI2="1.0937968510944742" CI_END="0.9156467017134419" CI_START="0.3204123683471327" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.541649820700833" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="28" I2="8.575344772717099" I2_Q="5.333737944494699" ID="CMP-001.01" LOG_CI_END="-0.038272064644071215" LOG_CI_START="-0.4942907279147818" LOG_EFFECT_SIZE="-0.2662813962794265" METHOD="MH" MODIFIED="2013-11-15 17:21:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2956319546972608" P_Q="0.304051223999493" P_Z="0.02208226102216583" Q="1.0563425430420754" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.022959342579643372" TOTALS="SUB" TOTAL_1="100" TOTAL_2="90" WEIGHT="200.0" Z="2.288949942168891">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Active placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0989548853310618" CI_START="0.3450520862701688" DF="0" EFFECT_SIZE="0.6157894736842106" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.04097986398496685" LOG_CI_START="-0.4621153423983015" LOG_EFFECT_SIZE="-0.2105677392066673" NO="1" P_CHI2="1.0" P_Z="0.1008671088507791" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.0" Z="1.6406643510599592">
<NAME>Any reason</NAME>
<DICH_DATA CI_END="1.0989548853310618" CI_START="0.3450520862701688" EFFECT_SIZE="0.6157894736842106" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.04097986398496685" LOG_CI_START="-0.4621153423983015" LOG_EFFECT_SIZE="-0.2105677392066673" ORDER="9114" O_E="0.0" SE="0.29552061459096746" STUDY_ID="STD-Bender-1997" TOTAL_1="50" TOTAL_2="45" VAR="0.08733243364822312" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0398285012254938" CI_START="0.08655273431525501" DF="0" EFFECT_SIZE="0.29999999999999993" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.016961717074595855" LOG_CI_START="-1.0627192076352712" LOG_EFFECT_SIZE="-0.5228787452803376" NO="2" P_CHI2="1.0" P_Z="0.05764575649220592" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.0" Z="1.8983821712073803">
<NAME>Inefficacy of treatment</NAME>
<DICH_DATA CI_END="1.0398285012254938" CI_START="0.08655273431525501" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.016961717074595855" LOG_CI_START="-1.0627192076352712" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="9115" O_E="0.0" SE="0.6342099196813482" STUDY_ID="STD-Bender-1997" TOTAL_1="50" TOTAL_2="45" VAR="0.4022222222222222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8097757196881019" CI_START="0.22682017368772162" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4285714285714285" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.09163524925637097" LOG_CI_START="-0.644318321332818" LOG_EFFECT_SIZE="-0.3679767852945945" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.009057111599661126" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.0" Z="2.6098908497941995">
<NAME>Global state: Change over time - no better or deterioration</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Active placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8097757196881019" CI_START="0.22682017368772167" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.09163524925637097" LOG_CI_START="-0.6443183213328179" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="9116" O_E="0.0" SE="0.3246487723630345" STUDY_ID="STD-Bender-1997" TOTAL_1="50" TOTAL_2="45" VAR="0.1053968253968254" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0481927260889627" CI_START="0.46747128443477903" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.020441141599749267" LOG_CI_START="-0.3302450615712357" LOG_EFFECT_SIZE="-0.1549019599857432" METHOD="MH" MODIFIED="2013-11-15 17:22:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.08336701306386834" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.0" Z="1.7314753757717303">
<NAME>Mental state: 1a. General - Less than 20% BPRS reduction</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0481927260889627" CI_START="0.46747128443477903" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="27" LOG_CI_END="0.020441141599749267" LOG_CI_START="-0.3302450615712357" LOG_EFFECT_SIZE="-0.1549019599857432" ORDER="9117" O_E="0.0" SE="0.2059948116673389" STUDY_ID="STD-Bender-1997" TOTAL_1="50" TOTAL_2="45" VAR="0.04243386243386242" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0899611300691445" CI_START="0.6141700553677903" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.03741101051174113" LOG_CI_START="-0.21171136194954143" LOG_EFFECT_SIZE="-0.08715017571890014" METHOD="MH" MODIFIED="2013-11-15 17:22:34 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.17028032754544753" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="45" WEIGHT="99.99999999999999" Z="1.3713036205283253">
<NAME>Mental state: 1b. General - Less than 30% BPRS reduction</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0899611300691445" CI_START="0.6141700553677903" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="33" LOG_CI_END="0.03741101051174113" LOG_CI_START="-0.21171136194954143" LOG_EFFECT_SIZE="-0.08715017571890014" ORDER="9118" O_E="0.0" SE="0.1463357147593895" STUDY_ID="STD-Bender-1997" TOTAL_1="50" TOTAL_2="45" VAR="0.021414141414141403" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.804034281195273" CI_START="-13.204034281195279" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2013-11-15 17:22:48 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.08274643906542116" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="1.7349681935129788">
<NAME>Mental state: 1c. General - BPRS endpoint score - per protocol sample (high=poor)</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.804034281195273" CI_START="-13.204034281195279" EFFECT_SIZE="-6.200000000000003" ESTIMABLE="YES" MEAN_1="37.9" MEAN_2="44.1" ORDER="9119" SD_1="12.9" SD_2="17.9" SE="3.573552543027425" STUDY_ID="STD-Bender-1997" TOTAL_1="43" TOTAL_2="36" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.04249270089041987" CI_END="-1.910155235640289" CI_START="-11.379717211043861" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.644936223342075" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2013-11-15 17:23:02 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8366835646037757" P_Q="0.8366835646037757" P_Z="0.005947292282312337" Q="0.04249270089041987" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="93" TOTAL_2="81" UNITS="" WEIGHT="200.0" Z="2.7506733069902163">
<NAME>Mental state: 1d. General - BPRS change from baseline to endpoint (high=poor)</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.918814452311218" CI_START="-13.118814452311216" DF="0" EFFECT_SIZE="-6.1" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.08849505574769065" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="36" WEIGHT="100.0" Z="1.7033902786470476">
<NAME>per protocol analysis</NAME>
<CONT_DATA CI_END="0.918814452311218" CI_START="-13.118814452311216" EFFECT_SIZE="-6.1" ESTIMABLE="YES" MEAN_1="-18.5" MEAN_2="-12.4" ORDER="9120" SD_1="15.3" SD_2="16.3" SE="3.581093585226428" STUDY_ID="STD-Bender-1997" TOTAL_1="43" TOTAL_2="36" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.686028050550183" CI_START="-13.51397194944982" DF="0" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="1.0" P_Z="0.03003727075172439" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.00000000000001" Z="2.1695985576344876">
<NAME>intent-to-treat analysis</NAME>
<CONT_DATA CI_END="-0.686028050550183" CI_START="-13.51397194944982" EFFECT_SIZE="-7.100000000000001" ESTIMABLE="YES" MEAN_1="-19.8" MEAN_2="-12.7" ORDER="9121" SD_1="15.5" SD_2="16.3" SE="3.272494800946553" STUDY_ID="STD-Bender-1997" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5075121710124173" CI_START="0.8746446501488081" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1482758620689655" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.1782608271353692" LOG_CI_START="-0.058168355920641644" LOG_EFFECT_SIZE="0.06004623560736377" METHOD="MH" MODIFIED="2013-11-15 17:23:17 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.3194691704158402" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.0" Z="0.9955493452748496">
<NAME>Adverse events: 1. General - at least one adverse event</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Active placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5075121710124173" CI_START="0.8746446501488081" EFFECT_SIZE="1.1482758620689655" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="29" LOG_CI_END="0.1782608271353692" LOG_CI_START="-0.058168355920641644" LOG_EFFECT_SIZE="0.06004623560736377" ORDER="9122" O_E="0.0" SE="0.13887967247043195" STUDY_ID="STD-Bender-1997" TOTAL_1="50" TOTAL_2="45" VAR="0.019287563425494456" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="230.37287620411234" CI_START="0.7945596101199973" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="13.529411764705884" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="2.362431344506734" LOG_CI_START="-0.09987351522809632" LOG_EFFECT_SIZE="1.131278914639319" METHOD="MH" MODIFIED="2013-11-15 17:23:33 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.07170794945328772" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.0" Z="1.800967837428066">
<NAME>Adverse events: 2. Movement disorder - at least one extrapyramidal side-effect</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Active placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="230.37287620411234" CI_START="0.7945596101199973" EFFECT_SIZE="13.529411764705882" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.362431344506734" LOG_CI_START="-0.09987351522809632" LOG_EFFECT_SIZE="1.131278914639319" ORDER="9123" O_E="0.0" SE="1.4463700632138705" STUDY_ID="STD-Bender-1997" TOTAL_1="50" TOTAL_2="45" VAR="2.0919863597612958" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.450390045688362" CI_START="1.0411102272208104" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="1.288928314812969" LOG_CI_START="0.01749671273771822" LOG_EFFECT_SIZE="0.6532125137753437" METHOD="MH" MODIFIED="2013-11-15 17:23:57 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.044019215969702666" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.0" Z="2.0139077857760745">
<NAME>Adverse events: 3. Movement disorder - use of antiparkinson medication</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Active placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.450390045688362" CI_START="1.0411102272208104" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.288928314812969" LOG_CI_START="0.01749671273771822" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="9124" O_E="0.0" SE="0.7468452167469359" STUDY_ID="STD-Bender-1997" TOTAL_1="50" TOTAL_2="45" VAR="0.5577777777777777" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8097757196881019" CI_START="0.22682017368772167" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" I2="0.0" I2_Q="100.0" ID="CMP-001.10" LOG_CI_END="-0.09163524925637097" LOG_CI_START="-0.6443183213328179" LOG_EFFECT_SIZE="-0.36797678529459443" METHOD="MH" MODIFIED="2013-11-15 17:24:13 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.00905711159966114" Q="1.1694803517724902E-31" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="45" WEIGHT="100.0" Z="2.609890849794199">
<NAME>Sensitivity analysis: fixed effects model - global state no better or worse</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Active placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8097757196881019" CI_START="0.22682017368772167" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="-0.09163524925637097" LOG_CI_START="-0.6443183213328179" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2013-02-07 17:18:10 +0000" MODIFIED_BY="[Empty name]" ORDER="9116" O_E="0.0" SE="0.3246487723630345" STUDY_ID="STD-Bender-1997" TOTAL_1="50" TOTAL_2="45" VAR="0.1053968253968254" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-12-11 09:38:29 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Perazine versus other antipsychotics</NAME>
<DICH_OUTCOME CHI2="5.63220879105854" CI_END="1.3834465020732183" CI_START="0.6843802357812736" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9730382537596594" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="67" I2="11.224882004768862" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.1409623696181954" LOG_CI_START="-0.16470254094138756" LOG_EFFECT_SIZE="-0.01187008566159612" METHOD="MH" MODIFIED="2013-11-15 17:25:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3436664955681442" P_Q="1.0" P_Z="0.8790093740192161" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.023213615976850153" TOTALS="YES" TOTAL_1="158" TOTAL_2="226" WEIGHT="100.0" Z="0.15222513011089428">
<NAME>Leaving the study early due to any reason</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8592753848835426" CI_START="0.7869126604227532" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.45625598549989865" LOG_CI_START="-0.10407346738853616" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="9125" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.10833333333333332" WEIGHT="24.506742913269157"/>
<DICH_DATA CI_END="1.1204566310794288" CI_START="0.25877023738352345" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.04939505119022204" LOG_CI_START="-0.5870856757753821" LOG_EFFECT_SIZE="-0.26884531229257996" ORDER="9126" O_E="0.0" SE="0.373871929650007" STUDY_ID="STD-Klimke-1993" TOTAL_1="25" TOTAL_2="25" VAR="0.13978021978021976" WEIGHT="19.7785839740242"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="9127" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-R_x00fc_ther-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="4.457586522918436"/>
<DICH_DATA CI_END="5.5162686574153295" CI_START="0.14113647488075015" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7416454093514776" LOG_CI_START="-0.8503607339966631" LOG_EFFECT_SIZE="-0.0543576623225927" ORDER="9128" O_E="0.0" SE="0.9351522891602034" STUDY_ID="STD-Schmidt-1982" TOTAL_1="17" TOTAL_2="15" VAR="0.8745098039215686" WEIGHT="3.591069583696838"/>
<DICH_DATA CI_END="1.8331513337535346" CI_START="0.7243425068037652" EFFECT_SIZE="1.1523148148148148" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="36" LOG_CI_END="0.26319831913633" LOG_CI_START="-0.14005602822100538" LOG_EFFECT_SIZE="0.06157114545766232" MODIFIED="2013-02-17 11:20:23 +0000" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.2368735997789116" STUDY_ID="STD-Tybura-2012" TOTAL_1="60" TOTAL_2="131" VAR="0.05610910227221999" WEIGHT="40.64141193002179"/>
<DICH_DATA CI_END="2.0836686717842268" CI_START="0.15670946953638873" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.31882866210558825" LOG_CI_START="-0.8049047594781773" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="9129" O_E="0.0" SE="0.6600865744084526" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.4357142857142857" WEIGHT="7.024605076069584"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.965261095458803" CI_START="0.35804316099383415" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.4460646173460429" LOG_EFFECT_SIZE="0.12493873660829993" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6680315801223178" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.4288511132734677">
<NAME>Global state: 1. No better or deterioration</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.4460646173460429" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="9130" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-R_x00fc_ther-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.6876792213690512" CI_START="1.012320778630948" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.8499999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.5009671822689229E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="4.328546392105915">
<NAME>Global state: 2. CGI severity score at endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.6876792213690512" CI_START="1.012320778630948" EFFECT_SIZE="1.8499999999999996" ESTIMABLE="YES" MEAN_1="5.85" MEAN_2="4.0" ORDER="9131" SD_1="0.7" SD_2="1.5" SE="0.42739521132865615" STUDY_ID="STD-R_x00fc_ther-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-2.8758868561911672" CI_START="-17.124113143808835" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.005938298306526877" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="2.7511690858578643">
<NAME>Global state: 3. GAS endpoint score (low = poor)</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours perazine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.8758868561911672" CI_START="-17.124113143808835" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="55.0" MEAN_2="65.0" ORDER="9132" SD_1="14.5" SD_2="8.0" SE="3.6348183946250687" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.615599472493069" CI_START="0.5291647515372279" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.4175712411034149" LOG_CI_START="-0.2764090925320003" LOG_EFFECT_SIZE="0.07058107428570728" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6901325670398331" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="0.3986751695554757">
<NAME>Mental state: 1a. General - BPRS - no better or deterioration</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.615599472493069" CI_START="0.5291647515372279" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.4175712411034149" LOG_CI_START="-0.2764090925320003" LOG_EFFECT_SIZE="0.07058107428570728" ORDER="9133" O_E="0.0" SE="0.40764748323549754" STUDY_ID="STD-Schmidt-1982" TOTAL_1="17" TOTAL_2="15" VAR="0.16617647058823526" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="14.738710195253926" CI_START="1.1012898047460773" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.920000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.022815039758801565" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="2.276517745007224">
<NAME>Mental state: 1b. General - BPRS endpoint score (high = poor)</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.738710195253926" CI_START="1.1012898047460773" EFFECT_SIZE="7.920000000000002" ESTIMABLE="YES" MEAN_1="34.02" MEAN_2="26.1" ORDER="9134" SD_1="12.96" SD_2="6.66" SE="3.4789977004878865" STUDY_ID="STD-Wetzel-1991" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.05770700557684394" CI_START="-0.7422929944231563" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.021998525421512108" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="2.2903933372554737">
<NAME>Mental state: 1c. General - BPRS endpoint score: separate items (high = poor)</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.05770700557684394" CI_START="-0.7422929944231563" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="2.1" ORDER="9135" SD_1="0.5" SD_2="0.6" SE="0.1746424919657298" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="10.401339251945835" CI_START="-2.8013392519458327" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.8000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2013-02-17 11:30:09 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.2592206312127965" Q="0.0" RANDOM="YES" SCALE="17.2908791525797" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="131" UNITS="" WEIGHT="100.0" Z="1.128235174257534">
<NAME>Mental state: 1d. General - percentage PANSS change from baseline</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.401339251945835" CI_START="-2.8013392519458327" EFFECT_SIZE="3.8000000000000007" ESTIMABLE="YES" MEAN_1="-24.0" MEAN_2="-27.8" MODIFIED="2013-02-17 11:30:05 +0000" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="21.7" SD_2="21.4" SE="3.3680921200676925" STUDY_ID="STD-Tybura-2012" TOTAL_1="60" TOTAL_2="131" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.022993400103283657" CI_START="-0.7770065998967162" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.03757132785325617" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="2.079500979640145">
<NAME>Mental state: 1e. Specific - BPRS positive symptoms subscore at endpoint (high = poor)</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.022993400103283657" CI_START="-0.7770065998967162" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.9" ORDER="9136" SD_1="0.5" SD_2="0.7" SE="0.19235384061671346" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-002.10" MODIFIED="2013-11-15 17:14:29 +0000" MODIFIED_BY="[Empty name]" NO="10" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Mental state: 2. Unable to use (skewed data)</NAME>
<TR>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA ORDER="75" STUDY_ID="STD-R_x00fc_ther-1988">
<TR>
<TD>
<P>Mean BPRS-score at endpoint<BR/>Perazine</P>
</TD>
<TD>
<P>42.9</P>
</TD>
<TD>
<P>18.0</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
<TR>
<TD>
<P>Amisulpride</P>
</TD>
<TD>
<P>37.9</P>
</TD>
<TD>
<P>19.5</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="76" STUDY_ID="STD-Schmidt-1982">
<TR>
<TD>
<P>Mean AMDP-score at endpoint:<BR/>Perazine</P>
</TD>
<TD>
<P>10.2</P>
</TD>
<TD>
<P>11.8</P>
</TD>
<TD>
<P>17</P>
</TD>
</TR>
<TR>
<TD>
<P>Haloperidol</P>
</TD>
<TD>
<P>11.4</P>
</TD>
<TD>
<P>13.7</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="5.11348473086159" CI_END="1.2828428692234004" CI_START="0.42221445849362427" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7359584277400221" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="27" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.10817346447442812" LOG_CI_START="-0.3744668986065674" LOG_EFFECT_SIZE="-0.13314671706606962" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.6461163562721414" P_Q="0.42825539299296755" P_Z="0.27952084895474305" Q="3.8388424964046566" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="185" WEIGHT="500.0" Z="1.0813963773910347">
<NAME>Adverse events: 1. Movement disorder</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2920617897917622" CI_END="1.0499279497514193" CI_START="0.09251643484164944" DF="1" EFFECT_SIZE="0.3116658318642" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="0.021159497070879656" LOG_CI_START="-1.0337811112930213" LOG_EFFECT_SIZE="-0.5063108071110708" NO="1" P_CHI2="0.588902384297207" P_Z="0.05992569212163666" STUDIES="3" TAU2="0.0" TOTAL_1="56" TOTAL_2="55" WEIGHT="100.00000000000001" Z="1.8813399333638972">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="1.8255673991975914" CI_START="0.08764398404042836" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2613978715554003" LOG_CI_START="-1.0572778888994754" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="9139" O_E="0.0" SE="0.7745966692414833" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.5999999999999999" WEIGHT="64.00000000000001"/>
<DICH_DATA CI_END="1.5140742356037356" CI_START="0.02641878387425968" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1801471693005652" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="9140" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-R_x00fc_ther-1988" TOTAL_1="15" TOTAL_2="15" VAR="1.0666666666666667" WEIGHT="36.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9141" O_E="0.0" SE="0.0" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5918712049058212" CI_END="3.4777162361813003" CI_START="0.06358740190674955" DF="1" EFFECT_SIZE="0.4702541228183849" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-002.11.02" LOG_CI_END="0.5412941429087165" LOG_CI_START="-1.1966289193254442" LOG_EFFECT_SIZE="-0.32766738820836394" NO="2" P_CHI2="0.4416965974475968" P_Z="0.459869472794315" STUDIES="3" TAU2="0.0" TOTAL_1="56" TOTAL_2="55" WEIGHT="100.0" Z="0.739061807455511">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="3.919915520931636" CI_START="0.0102043015433387" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5932767075335775" LOG_CI_START="-1.991216716205615" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="9142" O_E="0.0" SE="1.5181442305531794" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="2.304761904761905" WEIGHT="45.217883418222975"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9143" O_E="0.0" SE="0.0" STUDY_ID="STD-R_x00fc_ther-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.218244504526753" CI_START="0.06379335213776025" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1528459783163107" LOG_CI_START="-1.1952245764561868" LOG_EFFECT_SIZE="-0.021189299069938095" ORDER="9144" O_E="0.0" SE="1.3792682670100667" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.9023809523809523" WEIGHT="54.782116581777025"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.770423965889751" CI_START="0.012966912506691929" DF="0" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.11.03" LOG_CI_END="0.8306158651816438" LOG_CI_START="-1.8871634195157312" LOG_EFFECT_SIZE="-0.5282737771670437" NO="3" P_CHI2="1.0" P_Z="0.4460935360456839" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="0.7619438289593377">
<NAME>neuroleptic malignant syndrome</NAME>
<DICH_DATA CI_END="6.770423965889751" CI_START="0.012966912506691929" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8306158651816438" LOG_CI_START="-1.8871634195157312" LOG_EFFECT_SIZE="-0.5282737771670437" ORDER="9145" O_E="0.0" SE="1.596437005055668" STUDY_ID="STD-Schmidt-1982" TOTAL_1="17" TOTAL_2="15" VAR="2.548611111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.29116809299709046" CI_END="2.758109333728247" CI_START="0.5284855564115489" DF="1" EFFECT_SIZE="1.2073197363910106" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-002.11.04" LOG_CI_END="0.4406114779724335" LOG_CI_START="-0.2769668775268109" LOG_EFFECT_SIZE="0.08182230022281135" NO="4" P_CHI2="0.5894730360910858" P_Z="0.6548951870733754" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.4469721260122449">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="2.925649438310225" CI_START="0.3418044509726267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4662222862019852" LOG_CI_START="-0.46622228620198514" LOG_EFFECT_SIZE="0.0" ORDER="9146" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.30000000000000004" WEIGHT="59.22330097087378"/>
<DICH_DATA CI_END="5.787968532733963" CI_START="0.4353040820455243" EFFECT_SIZE="1.5873015873015872" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.762526161338301" LOG_CI_START="-0.36120726024546446" LOG_EFFECT_SIZE="0.20065945054641826" ORDER="9147" O_E="0.0" SE="0.6600865744084526" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.4357142857142857" WEIGHT="40.77669902912621"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.550748330704528" CI_START="0.25090676030089926" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-002.11.05" LOG_CI_END="0.40666761110760385" LOG_CI_START="-0.6004876371237168" LOG_EFFECT_SIZE="-0.09691001300805639" NO="5" P_CHI2="1.0" P_Z="0.706038770313687" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.37718144361687084">
<NAME>tremor</NAME>
<DICH_DATA CI_END="2.550748330704528" CI_START="0.25090676030089926" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.40666761110760385" LOG_CI_START="-0.6004876371237168" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="9148" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6283898378435606" CI_END="1.9034679657473919" CI_START="0.40181082626668274" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8745479038275269" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.27954557228975724" LOG_CI_START="-0.3959783659338682" LOG_EFFECT_SIZE="-0.0582163968220555" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.652969943455744" P_Q="1.0" P_Z="0.735500416023187" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="95" WEIGHT="100.0" Z="0.3378179058493956">
<NAME>Adverse events: 2. Leaving the study early due to adverse events</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9149" O_E="0.0" SE="0.0" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.030486172073819" CI_START="0.32998005706644784" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.481512306690943" LOG_CI_START="-0.4815123066909431" LOG_EFFECT_SIZE="0.0" ORDER="9150" O_E="0.0" SE="0.5656854249492381" STUDY_ID="STD-Klimke-1993" TOTAL_1="25" TOTAL_2="25" VAR="0.32000000000000006" WEIGHT="49.204714103723404"/>
<DICH_DATA CI_END="3.436173203095408" CI_START="0.1293428526955729" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5360750466763062" LOG_CI_START="-0.8882575647876688" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="9151" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-R_x00fc_ther-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.7" WEIGHT="22.49358359027356"/>
<DICH_DATA CI_END="3.433298501240456" CI_START="0.00920541521810178" EFFECT_SIZE="0.17777777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5357115639284808" LOG_CI_START="-2.0359566174952812" LOG_EFFECT_SIZE="-0.7501225267834001" ORDER="9152" O_E="0.0" SE="1.510610619731122" STUDY_ID="STD-Schmidt-1982" TOTAL_1="17" TOTAL_2="15" VAR="2.2819444444444446" WEIGHT="6.900040249237902"/>
<DICH_DATA CI_END="7.67378760307657" CI_START="0.26594641813026065" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8850097745224009" LOG_CI_START="-0.5752058545509147" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="9153" O_E="0.0" SE="0.8577378887016042" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.7357142857142855" WEIGHT="21.40166205676514"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.20938660574449308" CI_END="3.2525562289748957" CI_START="0.17872548922041043" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7624399669747326" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.5122248132190006" LOG_CI_START="-0.7478135054777684" LOG_EFFECT_SIZE="-0.11779434612938396" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.647248614377707" P_Q="0.647636761854376" P_Z="0.7140267645595199" Q="0.20889261474704407" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="200.0" Z="0.3664534206147388">
<NAME>Adverse events: 3. Anticholinergic</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.41978801003991" CI_START="0.15576838338526122" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="0.8075206873227565" LOG_CI_START="-0.8075206873227565" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>dry mouth</NAME>
<DICH_DATA CI_END="6.41978801003991" CI_START="0.15576838338526122" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8075206873227565" LOG_CI_START="-0.8075206873227565" LOG_EFFECT_SIZE="0.0" ORDER="9154" O_E="0.0" SE="0.9486832980505138" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.8999999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.083060192649951" CI_START="0.04918297059741634" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.13.02" LOG_CI_END="0.7061252525673394" LOG_CI_START="-1.3081852438953019" LOG_EFFECT_SIZE="-0.3010299956639812" NO="2" P_CHI2="1.0" P_Z="0.5579989793003175" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.585816288803313">
<NAME>blurred vision</NAME>
<DICH_DATA CI_END="5.083060192649951" CI_START="0.04918297059741634" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7061252525673394" LOG_CI_START="-1.3081852438953019" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="9155" O_E="0.0" SE="1.1832159566199232" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="1.4" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9532080098653688" CI_START="0.391983340296036" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.290748496603893" LOG_CI_START="-0.4067323905592665" LOG_EFFECT_SIZE="-0.057991946977686754" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.7444834908465342" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.3259218411902773">
<NAME>Adverse events: 4. Arousal</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9532080098653688" CI_START="0.391983340296036" DF="0" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="0.290748496603893" LOG_CI_START="-0.4067323905592665" LOG_EFFECT_SIZE="-0.057991946977686754" NO="1" P_CHI2="1.0" P_Z="0.7444834908465342" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.3259218411902773">
<NAME>drowsiness / sedation</NAME>
<DICH_DATA CI_END="1.9532080098653688" CI_START="0.391983340296036" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.290748496603893" LOG_CI_START="-0.4067323905592665" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="9156" O_E="0.0" SE="0.40970372570571395" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.16785714285714287" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.7241375997437185" CI_END="4.1903701239783375" CI_START="0.5046995146826009" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.454261932360308" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="36.49634591162738" I2_Q="66.06620750178458" ID="CMP-002.15" LOG_CI_END="0.6222523847090676" LOG_CI_START="-0.2969671128822637" LOG_EFFECT_SIZE="0.162642635913402" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.19314813732547154" P_Q="0.08604182867848265" P_Z="0.48794894874242" Q="2.9469149375289834" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.8572639595295973" TOTALS="SUB" TOTAL_1="95" TOTAL_2="90" WEIGHT="200.0" Z="0.6935747328602679">
<NAME>Adverse events: 5. Abnormal laboratory results</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>leukopenia</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9157" O_E="0.0" SE="0.0" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.483825290866965" CI_START="0.007486453008868247" DF="0" EFFECT_SIZE="0.13636363636363635" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.15.02" LOG_CI_END="0.39512104485364247" LOG_CI_START="-2.12572389705873" LOG_EFFECT_SIZE="-0.8653014261025438" NO="2" P_CHI2="1.0" P_Z="0.1784481531552583" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="20" WEIGHT="100.0" Z="1.3455485521815063">
<NAME>leukocytosis</NAME>
<DICH_DATA CI_END="2.483825290866965" CI_START="0.007486453008868247" EFFECT_SIZE="0.13636363636363635" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39512104485364247" LOG_CI_START="-2.12572389705873" LOG_EFFECT_SIZE="-0.8653014261025438" ORDER="9158" O_E="0.0" SE="1.4807567972630389" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="2.1926406926406927" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9293882567272644" CI_END="6.514538690827959" CI_START="0.6709524584389841" DF="2" EFFECT_SIZE="2.0906806906380755" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" ID="CMP-002.15.03" LOG_CI_END="0.8138836677660084" LOG_CI_START="-0.1733082514689882" LOG_EFFECT_SIZE="0.3202877081485101" NO="3" P_CHI2="0.3810998298166982" P_Z="0.20344635191843607" STUDIES="3" TAU2="0.0" TOTAL_1="53" TOTAL_2="50" WEIGHT="100.0" Z="1.27179398540543">
<NAME>increase of transaminases</NAME>
<DICH_DATA CI_END="153.7923213075611" CI_START="0.5266842928914012" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1869346521298794" LOG_CI_START="-0.27844963325122957" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="9159" O_E="0.0" SE="1.4481789330818973" STUDY_ID="STD-R_x00fc_ther-1988" TOTAL_1="15" TOTAL_2="15" VAR="2.0972222222222223" WEIGHT="16.033706764195124"/>
<DICH_DATA CI_END="85.83246253101137" CI_START="0.23013538045254459" EFFECT_SIZE="4.444444444444445" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9336515726005183" LOG_CI_START="-0.6380166088232434" LOG_EFFECT_SIZE="0.6478174818886375" ORDER="9160" O_E="0.0" SE="1.510610619731122" STUDY_ID="STD-Schmidt-1982" TOTAL_1="17" TOTAL_2="15" VAR="2.2819444444444446" WEIGHT="14.735786496612679"/>
<DICH_DATA CI_END="4.9771310503874995" CI_START="0.3239811920296023" EFFECT_SIZE="1.2698412698412698" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6969790760887775" LOG_CI_START="-0.48948020101205375" LOG_EFFECT_SIZE="0.10374943753836186" ORDER="9161" O_E="0.0" SE="0.6969320524371695" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.4857142857142856" WEIGHT="69.2305067391922"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.091986634774602" CI_END="5.718259119899878" CI_START="0.12176414403002697" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8344332969605803" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="75.56199251723405" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.7572638312935532" LOG_CI_START="-0.9144805798676229" LOG_EFFECT_SIZE="-0.07860837428703485" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.04308707282756896" P_Q="1.0" P_Z="0.8537609070449272" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.4637857362246431" TOTALS="YES" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.00000000000001" Z="0.18432193516808903">
<NAME>Adverse events: 6. Cardiovascular</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.091986634774602" CI_END="5.718259119899878" CI_START="0.12176414403002697" DF="1" EFFECT_SIZE="0.8344332969605803" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="75.56199251723405" ID="CMP-002.16.01" LOG_CI_END="0.7572638312935532" LOG_CI_START="-0.9144805798676229" LOG_EFFECT_SIZE="-0.07860837428703485" NO="1" P_CHI2="0.04308707282756896" P_Z="0.8537609070449272" STUDIES="2" TAU2="1.4637857362246431" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.00000000000001" Z="0.18432193516808903">
<NAME>hypotension - orthostatic</NAME>
<DICH_DATA CI_END="1.0530372514691644" CI_START="0.10551489128812148" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.022443734738520807" LOG_CI_START="-0.9766862441778457" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="9162" O_E="0.0" SE="0.5868938953886337" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.34444444444444444" WEIGHT="53.3287311114413"/>
<DICH_DATA CI_END="10.899222152660482" CI_START="0.5201228272036859" EFFECT_SIZE="2.380952380952381" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0373955046505794" LOG_CI_START="-0.2838940854463801" LOG_EFFECT_SIZE="0.37675070960209955" ORDER="9163" O_E="0.0" SE="0.7761320457119086" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.6023809523809522" WEIGHT="46.671268888558714"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.804839072539661" CI_START="0.03593113563936224" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31746031746031744" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.44790794868917194" LOG_CI_START="-1.444529056268373" LOG_EFFECT_SIZE="-0.49831055378960054" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.301986369347478" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="20" WEIGHT="100.0" Z="1.032183090887865">
<NAME>Adverse events: 7. EEG-changes</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.804839072539661" CI_START="0.03593113563936224" EFFECT_SIZE="0.31746031746031744" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.44790794868917194" LOG_CI_START="-1.444529056268373" LOG_EFFECT_SIZE="-0.49831055378960054" ORDER="9164" O_E="0.0" SE="1.111626864426317" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="1.2357142857142855" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.723921203524791" CI_START="0.014385324265142151" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.49327758741034344" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6851051308492764">
<NAME>Adverse events: 8. Hypersalivation</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="9165" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Dieterle-1991" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.0844858506529786" CI_START="0.726152621885666" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4965986394557824" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.4891827823616716" LOG_CI_START="-0.13897209021361123" LOG_EFFECT_SIZE="0.17510534607403017" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.2745147093370951" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="20" WEIGHT="100.0" Z="1.0927246982849428">
<NAME>Adverse events: 9. Vegetative</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0844858506529786" CI_START="0.726152621885666" EFFECT_SIZE="1.4965986394557824" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.4891827823616716" LOG_CI_START="-0.13897209021361123" LOG_EFFECT_SIZE="0.17510534607403017" ORDER="9166" O_E="0.0" SE="0.3689812815674884" STUDY_ID="STD-Wetzel-1991" TOTAL_1="21" TOTAL_2="20" VAR="0.13614718614718613" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.965261095458803" CI_START="0.35804316099383415" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.4460646173460429" LOG_EFFECT_SIZE="0.12493873660829993" METHOD="MH" MODIFIED="2013-11-15 17:24:54 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.6680315801223178" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.4288511132734677">
<NAME>Sensitivity analysis: fixed effects model - global state no better or worse</NAME>
<GROUP_LABEL_1>Perazine</GROUP_LABEL_1>
<GROUP_LABEL_2>Other antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours perazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.965261095458803" CI_START="0.35804316099383415" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6959420905626427" LOG_CI_START="-0.4460646173460429" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-02-07 17:20:00 +0000" MODIFIED_BY="[Empty name]" ORDER="9130" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-R_x00fc_ther-1988" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-12-11 09:37:50 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-02-26 14:43:56 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA1IAAAERCAYAAABxdZbsAAA2YElEQVR42u2dcWSW3///3ySZyUTm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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-12-11 09:37:50 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtYAAAEyCAMAAADp82f9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-12-11 09:37:50 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAXMAAAKfCAIAAAATtr+hAAAmoklEQVR42u3dv44Uy/nG8ZGQEAEB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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-07-10 13:21:04 +0100" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. June 2000<BR/>In the first version of the review we searched the Cochrane Schizophrenia Group Register (June 2000) with the phrase:</P>
<P>[perazin or perazine or pernazinum or taxilan or pernazine or #13 = "phenothiazine tranquilizers" or (#13 = piperazines) or perazin-neuraxpharm or methylpiperazin or piperazinyl]</P>
<P>2. March 2005<BR/>In the 2005 update we searched the Cochrane Schizophrenia Group's Trials Register (March 2005) with a slightly different phrase:</P>
<P>[((* perazin* or *pernazin* or *taxilan* or *phenothiazine tran* or * piperazin*) in Ti, Ab and In fields in Reference) AND (perazin* in Study Intervention field)]</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches of journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-07-10 13:24:11 +0100" MODIFIED_BY="[Empty name]">Previous data collection and analysis</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-11 09:37:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. Selection of trials<BR/>We (SL and BH) independently inspected all citations of those studies identified by the search. Where disagreement occurred we resolved this by discussion,and where there was still doubt, we acquired the full article for further inspection. Once the full articles were obtained BH decided whether they met the review criteria and this was checked by SL (this sequence was reversed in the 2005 update). We resolved any disagreement by discussion but if doubt remained we put the study on the list of those awaiting assessment pending acquisition of more information.</P>
<P>2. Quality assessment<BR/>We used criteria in the Cochrane Collaboration Handbook (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>) to assess trial quality. This simple set of criteria is based on evidence of strong association between overestimate of effect and poor concealment of allocation, and is defined as follows.</P>
<P>a. Low risk of bias (adequate allocation concealment).<BR/>b. Moderate risk of bias (some doubt about the results).<BR/>c. High risk of bias (inadequate allocation concealment).</P>
<P>The Jadad scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) measures a wider range of factors that impact on the quality of a trial. The scale includes three items.</P>
<P>a. Was the study described as randomised?<BR/>b. Was the study described as double blind?<BR/>c. Was there a description of withdrawals and dropouts?</P>
<P>Each item scores one point if the answer is positive and an additional point for the first two items if the means of randomisation/blinding is described. In addition, a point can be deducted if either the randomisation or the blinding/masking described were inadequate.</P>
<P>For the purpose of analysis of this review we included studies if they met criteria A and B of the Handbook. We gave studies not described as randomised a C rating and we excluded these. In addition, we used a cut-off of two points on the Jadad scale to check the assessment made by the handbook criteria. If a B rated study scored less than two on the Jadad scale we excluded it.</P>
<P>3. Data extraction<BR/>BH and SL independently extracted data from selected trials . When disputes arose we attempted resolution by discussion. If doubt remained and further information was necessary to resolve the dilemma, we did not enter the data but added them to the list of those awaiting assessment, pending further information.</P>
<P>4. Data synthesis<BR/>4.1 Data types<BR/>Outcomes are assessed using continuous (for example, average changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). Currently RevMan software does not support categorical data so we only presented these in the text of the review.</P>
<P>4.2 Incomplete data<BR/>With the exception of the outcome of leaving the study early, we did not include trial outcomes if more than 50% of people were not reported in the final analysis. We felt that such a degree of attrition would threaten the validity of the findings.</P>
<P>4.3 Dichotomous data<BR/>Where the original authors of the studies gave outcomes such as 'clinically improved' or 'not clinically improved' based on their clinical judgement, predetermined criteria or any scale, we recorded this in RevMan. If data was from a rater not clearly stated to be independent then we included if it did not change the results, otherwise we presented it separately with a label 'prone to bias'. Where possible, we tried to convert relevant categorical or continuous outcome measures to dichotomous data by identifying cut-off points on rating scales and dividing subjects accordingly into groups. This was with the cut-off points 'moderate or severe impairment' for end of study data or 'no better or worse' for change data. For example, the Brief Psychiatric Rating Scale (BPRS) (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) is frequently used as a measure of change of symptoms in studies. We defined a 50% change on this particular scale as clinically important, although, it was recognised that for many people, especially those with chronic or severe illnesses, a less rigorous definition of important improvement, for example, 20% on the BPRS, would be equally valid. If individual patient data were available we used the 50% cut-off for the definition in the case of non-chronically ill people and 20% for those with chronic illness.</P>
<P>We used an intention-to-treat analysis. As long as over 50% of people completed the study, everyone allocated to the intervention was counted whether or not they completed follow-up. We assumed that those who left the study early had no change as regards outcome.</P>
<P>We used the relative risk (RR) and 95% confidence interval (CI) based on the random-effects model, as this takes into account differences between studies even if heterogeneity is not statistically significant, as the preferred statistic for summation. We inspected data to see if analysis using a Mantel-Haenszel odds ratio and fixed-effect models made a substantive difference.</P>
<P>4.4 Continuous data<BR/>4.4.1 In the case of continuous data a post hoc application of intention to treat is not possible. Therefore, we could only use the data as presented by the original studies, i.e. either as intention to treat last observation carried forward data, or as data based on observed cases. If both analyses were presented we used the intention-to-treat results.<BR/>4.4.2 Rating scales: a wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. They were that: (a) the psychometric properties of the instrument should have been described in a peer-reviewed journal; (b) the instrument should either be: (i) a self-report or (ii) completed by an independent rater or relative (not the therapist). As it was expected that therapists would frequently also be the rater, such data will be commented on with 'prone to bias'; or (c) the instrument should be a global assessment of an area of functioning.</P>
<P>4.5 Normal distribution of data<BR/>Mental health continuous data are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data we applied the following standards to all data before inclusion:<BR/>4.5.1 standard deviations and means were reported in the paper or were obtained from the authors;<BR/>4.5.2 if the data were finite measures from, for example 0-100, when the standard deviation was multiplied by two, the result should be less than the mean. Otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Continuous data, if normally distributed, were summated using a calculation of the weighted mean difference (MD). We inspected data to see if analysis using a standardised mean difference made a substantive difference. Non-normally distributed data were reported in the 'Other data types' tables. We did not consider continuous data presented without use of summary statistics (i.e. mean, SD, SE, median, interquartile range), although we noted the existence of these data in the table of included studies. Furthermore, continuous data may be presented from different scales, rating the same outcome. In this event, we presented all data separately without summation and inspected the general direction of effect.</P>
<P>Endpoint scale-derived data is finite, ranging from one score to another. Change data is more problematic and you cannot apply the rule described above. Although most change scores are likely to be skewed, it cannot be proven so twe presented these in MetaView. Where both endpoint and change were available for the same outcome we presented endpoint in preference.</P>
<P>4.6 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra class correlation co-efficients of their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation co-efficient (ICC) Design effect = 1 + (m - 1) * ICC (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>4.7 Sensitivity analyses<BR/>4.7.1 We compared the outcome of the intention-to-treat analysis with a completer analysis.</P>
<P>5. Heterogeneity<BR/>Firstly, we considered all the included studies within any comparison to judge clinical heterogeneity. Then we visually inspected graphs to investigate the possibility of statistical heterogeneity. This was supplemented using, primarily, the I<SUP>2</SUP> statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I<SUP>2</SUP> estimate was greater than or equal to 75%, we interpreted this as indicating the presence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If inconsistency was high, we did not summate data, but presented them separately and investigated the reasons for heterogeneity.</P>
<P>6. Addressing publication bias<BR/>We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate overt publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
<P>7. Tables and figures<BR/>Where possible, we entered data into RevMan so the area to the left of the line of no effect indicated a favourable outcome for perazine.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 trials included (22 publications)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;103 records inspected&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;40 identified through original search in 2000&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2005 update search: 59 references identified&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2012 update search: four new references&lt;/p&gt;"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;24 full-text articles excluded, with reasons:&lt;/p&gt;&lt;p&gt;19: not randomised&lt;/p&gt;&lt;p&gt;1: wrong diagnosis&lt;/p&gt;&lt;p&gt;1: wrong intervention&lt;/p&gt;&lt;p&gt;3: no useable data&lt;/p&gt;"/>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>